| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Moleculin Biotech, Inc.$2.28
-0.15 (-6.31%)
D 38Pipeline Score Fair Value Pharma · Clinical
Market Cap
12.75 M
EPS
-28.04
P/E Ratio
-
Value Trade
341.12 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
5.38 M
Operating CF
-6.11 M
Total Assets
23.36 M
Total Liabilities
8.18 M
Equity
15.18 M
D/E Ratio
12,345
10.65 %
Week
-5.91 %
1 Month
-8.43 %
3 Month
-77.27 %
6 Month
-99.82 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
10.32 M
Monthly Burn
2.04 M
Runway
3.4 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
138.33 K
52 Week Range
1.79 - 24
% held by Insiders
0.83 %
% held by Institutions
3.21 %
Enterprise Value
2.76 M
Total Shares
5.34 M
Short %
21.83 %
Float Shares
4.93 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Moleculin Biotech, Inc.
910Total events
13Upcoming
168Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 13
2028
T1NDA Submission
Begin submission of Rolling NDA for accelerated approval on primary endpoint of CR from MIRACLE
2028
T2Rolling Submission Initiated
Begin submission of Rolling NDA for R/R AML for accelerated approval
Q3 2028
T1NDA Submission
Begin submission of NDA for accelerated approval on primary endpoint of CR from MIRACLE
Event history 897
Jul 6, 2026
▲Topline ReadoutAnnamycinClinical Data
Positive preliminary unblinded efficacy results from first 45 patients in Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemia (R/R AML)source ↗
Jul 6, 2026
▲Interim AnalysisAnnamycinTrial
Positive preliminary unblinded efficacy results from first 45 patients in Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
Q3 2026
▲Enrollment MilestoneAnnamycinTrial
90th subject enrollment expected in MIRACLE trial
relapsed/refractory acute myeloid leukemiasource ↗
Q3 2026
◆Topline ReadoutAnnamycinClinical Data
Complete unblinding of Part A data (90 subjects)
relapsed or refractory acute myeloid leukemiasource ↗
Q3 2026
◆Interim AnalysisAnnamycinTrial
Second unblinding of MIRACLE trial (Part A, 90 subjects)
Relapsed/Refractory Acute Myeloid Leukemiasource ↗
Jun 30, 2026
▲Interim AnalysisAnnamycinTrial
Positive interim efficacy results from Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
Jun 30, 2026
●Enrollment UpdateAnnamycinTrial
67 of 90 Part A patients enrolled (74%)
relapsed or refractory acute myeloid leukemiasource ↗
Jun 4, 2026
▲Enrollment MilestoneAnnamycinTrial
45th subject enrolled in MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
Jun 2026
◆Interim AnalysisAnnamycinTrial
45-patient interim data unblinding in MIRACLE trial
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)source ↗
May 30, 2026
◆Poster PresentationAnnamycinPresentation
Abstract accepted for poster presentation at 2026 ASCO Annual Meeting on pooled cardiac safety data for Annamycin
Acute Myeloid Leukemia (AML) and Soft Tissue Sarcomasource ↗
May 29, 2026
▲Poster PresentationAnnamycinPresentation
Poster presentation at ASCO 2026 on cardiac safety of L-annamycin at high cumulative anthracycline exposure
acute myeloid leukemia, soft tissue sarcomasource ↗
May 15, 2026
▲Enrollment MilestoneAnnamycinTrial
Enrollment of first 45 subjects achieved in MIRACLE trial
relapsed/refractory acute myeloid leukemiasource ↗
Drug Pipeline Intelligence
D38
Pipeline Score $13M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.0x
rNPV / MCap Top 53%
Micro Cap (rank 429 of 911)
Percentile RankMoleculin Biotech, Inc. faces pipeline headwinds (38/100), with $2.1B risk-adjusted pipeline value, led by MOL4239 in Psoriasis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOL4239 Small molecule | Psoriasis | Phase 2 | NCT01826201 | 33% | $1.8B | COMPLETED | 21 | - | - | Aug 1, 2013 | - | Dec 24, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Annamycin Fast TrackOrphan | relapsed or refractory acute myeloid leukemia | Phase 2/3 | 2026-07-06 | first 45 patients enrolled | Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment Read More | |
Annamycin Fast TrackOrphan | relapsed or refractory acute myeloid leukemia | Phase 2/3 | 2026-07-06 | first 45 patients enrolled | Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment Read More | |
Annamycin Fast TrackOrphan | relapsed or refractory acute myeloid leukemia | Phase 2/3 | 2026-07-06 | first 45 patients enrolled | Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MBRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MBRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MBRX▼ -9.1%on this news
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Moleculin Biotech's CEO Walter Klemp discussed the promising preliminary results from the first 45 patients in the Phase 2/3 MIRACLE trial for Annamycin, aimed at treating relapsed or refractory acute myeloid leukemia. The early data suggests potential efficacy and commercial opportunities, although the results are based on a limited sample size and have not yet reached statistical significance. The company is optimistic about the drug's future, pending further trials and necessary financing.
Read more →MBRX▼ -9.1%on this newsshared move
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment
Moleculin Biotech's CEO Walter Klemp discussed positive preliminary results from the Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia. The early efficacy trends observed across treatment arms are encouraging, and the company is optimistic about the commercial potential of Annamycin. However, the results are based on a limited patient sample and require further validation.
Read more →MBRX▼ -21.8%on this news· ran to -33% by day 3shared move
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Moleculin Biotech reported positive interim results from its Phase 2/3 MIRACLE trial, where both Annamycin treatment arms demonstrated significantly higher complete remission rates compared to the control arm in patients with relapsed or refractory acute myeloid leukemia. The interim analysis showed remission rates of 43% and 36% for Annamycin versus 12% for control, with ongoing enrollment in the trial. Despite the promising results, the analysis did not achieve statistical significance, and further data is needed as the trial progresses.
Read more →MBRXIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin’s Annamycin in Relapsed/Refractory AML
Moleculin Biotech's Annamycin shows strong physician interest for treating relapsed/refractory acute myeloid leukemia (R/R AML), with oncologists rating a likelihood to prescribe of 6 out of 7. Key factors include its efficacy, safety profile, and potential to bridge patients to bone marrow transplants. Payers also recognize its value in addressing significant unmet needs in this patient population.
Read more →MBRXMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin Biotech's CEO, Walter Klemp, announced the enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial for Annamycin combined with cytarabine, targeting relapsed or refractory acute myeloid leukemia. This milestone signals the upcoming interim data unblinding, expected in mid-2026, which could be crucial for the company's future. The company also highlighted the need for additional financing to continue its clinical trials.
Read more →MBRXMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin Biotech, Inc. has reached a significant milestone by enrolling the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia. This milestone is poised to trigger the final preparations for interim data unblinding expected by mid-2026. CEO Walter Klemp highlighted the potential of this trial phase to be a defining moment for the company, though he acknowledged the need for additional financing to support ongoing clinical developments.
Read more →MBRXMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Biotech presented new data at the 2026 ASCO Annual Meeting, showcasing the cardiac safety profile of Annamycin, its lead drug candidate. A pooled analysis from five clinical trials revealed no detectable cardiotoxicity despite high cumulative doses. The findings support Annamycin's potential to allow continued use of anthracyclines without the associated cardiac risks.
Read more →MBRXMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Biotech announced that its abstract on the cardiac safety of Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The findings indicate that Annamycin does not induce cardiotoxicity even at high cumulative doses, supporting its potential as a safer anthracycline therapy. The presentation will take place on May 30, 2026, in Chicago.
Read more →MBRXMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Moleculin Biotech, Inc. (MBRX) reported financial results for Q1 2026, highlighting promising progress in the pivotal MIRACLE trial for Annamycin in relapsed/refractory acute myeloid leukemia (AML). The trial has achieved a 40% complete remission rate and has surpassed the enrollment milestone for the first interim analysis. The company successfully raised $8.3 million to support its operations through mid-2026. Moleculin is also expanding its clinical operations in the US and Europe while bolstering its intellectual property strategy.
Read more →MBRX▼ -8.5%on this newsshared move
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Moleculin Biotech is nearing the unblinding of data from its pivotal MIRACLE trial, which evaluates Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia. Preliminary results indicate a 30% complete remission rate, marking a significant improvement over historical benchmarks. Recruitment for the trial continues, with expectations for the first unblinding before June 30, 2026.
Read more →MBRXIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin’s Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Moleculin Biotech announced a positive review of Annamycin's cardiac safety profile at the EHA 2026 Congress. The independent analysis of 90 patients showed no clinically significant cardiotoxicity, even in those with prior anthracycline exposure. This finding supports Annamycin's potential as a treatment option for relapsed/refractory acute myeloid leukemia, addressing a major limitation of traditional anthracyclines.
Read more →MBRXMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
Moleculin Biotech has announced the issuance of a Hong Kong patent for its method of reconstituting liposomal Annamycin, enhancing its global intellectual property portfolio. This patent, valid until June 2040, supports the company's strategy as it prepares for the release of Phase 3 clinical data. Annamycin aims to provide improved cancer treatment options with reduced cardiotoxicity.
Read more →MBRXMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models – Data Presented at AACR 2026
Moleculin Biotech presented promising preclinical data for Annamycin at AACR 2026, showing over 60% increased survival in metastatic pancreatic cancer models. The drug demonstrated significant tumor reduction and higher accumulation in pancreatic tissues compared to doxorubicin. Annamycin's lack of cardiotoxicity and immune activation capabilities suggest potential for broader applications in cancer therapy.
Read more →MBRXMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Moleculin Biotech presented preclinical data at AACR 2026 showing that Annamycin, a non-cardiotoxic anthracycline, significantly increases survival in metastatic pancreatic cancer models, extending median survival by over 60%. The drug also demonstrated a notable tumor volume reduction across various models and had enhanced tumor accumulation compared to doxorubicin. Results indicate that Annamycin could activate immune responses in pancreatic tumors. The company is optimistic about its potential applications beyond its current trials in acute myeloid leukemia.
Read more →MBRXMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
Moleculin Biotech announced that an abstract on annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The presentation will focus on the cardiac safety profile of annamycin in patients with high anthracycline exposure. This highlights the drug's potential advantages in treating certain cancers while minimizing cardiotoxicity risks.
Read more →MBRXMoleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
Moleculin Biotech has released a new CEO Corner segment highlighting Annamycin's non-cardiotoxic profile, which is a significant advantage over traditional anthracyclines. This profile may enhance treatment options for patients with relapsed or refractory acute myeloid leukemia and advanced solid tumors. The ongoing MIRACLE Study aims to further evaluate Annamycin's efficacy in combination with cytarabine.
Read more →MBRXMoleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
Moleculin Biotech announced the release of its CEO Corner segment that focuses on Annamycin's unique non-cardiotoxic profile. CEO Walter Klemp highlights this feature as a significant advantage over traditional anthracyclines, potentially offering new treatment options for patients with acute myeloid leukemia (AML). The company is advancing its MIRACLE Study, which evaluates Annamycin in combination with cytarabine for relapsed or refractory AML. While the outlook is positive, the company also faces challenges such as the need for further financing and the inherent risks in clinical trial outcomes.
Read more →MBRXMoleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Moleculin Biotech has reached a significant milestone with the enrollment of the 45th subject in its Phase 2B/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML). This milestone triggers the upcoming interim data unblinding, expected in mid-2026, which could provide critical insights into the efficacy of Annamycin combined with cytarabine. Early results indicate a 40% remission rate among difficult-to-treat patients, marking a potentially transformative moment for the company and its treatment approach.
Read more →MBRXMoleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Moleculin Biotech reported its 2025 financial results and highlighted progress in its pivotal MIRACLE trial for Annamycin in treating relapsed/refractory AML. The trial's preliminary data shows a 40% complete remission composite rate among the first 30 patients. The company anticipates unblinding data for 45 patients by mid-2026, marking a critical milestone in its clinical development.
Read more →MBRX▲ +5.4%on this newsshared move
Moleculin to Present at 38th Annual ROTH Conference
Moleculin Biotech, Inc. will participate in the 38th Annual ROTH Conference from March 22-24, 2026. The company will present a fireside chat featuring its leadership team. Moleculin is focused on developing innovative treatments for hard-to-treat tumors and viruses, including its lead program Annamycin for acute myeloid leukemia.
Read more →MBRXMoleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Moleculin Biotech, Inc. announced the release of a new CEO Corner segment featuring an update on the MIRACLE Study, which evaluates Annamycin combined with cytarabine for relapsed or refractory Acute Myeloid Leukemia. CEO Walter Klemp discussed the trial's progress, emphasizing the positive initial outcomes from a previous study. The Phase 3 trial, designed with FDA input, is currently enrolling patients and is expected to complete treatment for the first 45 patients soon. The company is optimistic about its pathway towards potential approval for Annamycin, though it faces financing challenges for continued clinical development.
Read more →MBRX▼ -44.3%on this news
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
Moleculin Biotech, Inc. has announced the immediate exercise of outstanding warrants, resulting in gross proceeds of approximately $8.3 million. The exercise involves 2,122,652 shares at an exercise price of $3.90 per share and will also lead to the issuance of new warrants for 6,367,956 shares. The funds will be allocated for working capital and general corporate purposes. The transaction is expected to close on February 20, 2026, subject to customary closing conditions.
Read more →MBRX▲ +5.5%on this news· ran to -49% by day 3shared move
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Moleculin Biotech announced a preliminary 40% complete remission composite rate in its MIRACLE trial for Annamycin combined with cytarabine in R/R AML patients. The trial, which has treated 35 subjects so far, is on track for unblinding data in Q1 2026. The results show a significant improvement over historical data, with no reported cardiotoxicity.
Read more →MBRX▲ +5.1%on this news· ran to -43% by day 3shared move
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
Moleculin Biotech announced a notice of allowance for a Japanese patent covering methods for reconstituting its drug candidate Annamycin. This patent is expected to enhance the company's intellectual property position as it advances Annamycin through Phase 3 development for acute myeloid leukemia. The drug is noted for its potential as a non-cardiotoxic treatment option.
Read more →MBRXMoleculin Launches CEO Corner Platform to Share Strategic Insights
Moleculin Biotech has launched its CEO Corner platform to enhance communication with investors and stakeholders. This initiative aims to provide deeper insights into the company's clinical progress and strategic initiatives. The platform allows users to submit questions for future discussions, emphasizing transparency and trust. The company continues to focus on its lead programs, including ongoing clinical trials.
Read more →MBRX▼ -6.5%on this news
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Moleculin Biotech, Inc. announced its participation in the Corporate Connect Webinar Series hosted by Webull Financial on February 11, 2026. Walter Klemp, the company's CEO, will present details about their ongoing clinical trials and therapeutic candidates, including Annamycin, which is in Phase 3 for treating acute myeloid leukemia. The webinar aims to engage investors and provide insights into Moleculin's innovative approaches in oncology.
Read more →MBRXMoleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Moleculin Biotech announced that Annamycin has shown no evidence of cardiotoxicity in 90 subjects across five clinical trials. The independent assessment confirms the safety of Annamycin, which is being evaluated for treating acute myeloid leukemia and soft tissue sarcoma. The company is optimistic about Annamycin's potential as a next-generation anthracycline.
Read more →MBRX▲ +5.9%on this newsshared move
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Biotech is advancing its pivotal Phase 2B/3 MIRACLE trial for Annamycin, with unblinding expected in Q1 2026. The trial is expanding globally to nine countries and includes new investigator-initiated trials for pancreatic cancer. The company aims to demonstrate Annamycin's efficacy and establish it as a non-cardiotoxic anthracycline, while also developing WP1066 for brain cancer treatment.
Read more →MBRX▼ -7.5%on this news
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Moleculin Biotech announced positive results from a Phase 1 clinical trial of WP1066, aimed at treating pediatric recurrent malignant brain tumors. Conducted at Emory University, the trial showed that WP1066 is safe and effective, inducing anti-tumor immune responses. The results support advancing to a Phase 2 trial, addressing a critical need in pediatric oncology.
Read more →MBRXMoleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Moleculin Biotech, Inc. has announced the exercise of warrants that will generate approximately $6.5 million in gross proceeds. The funds will support the company's ongoing clinical programs, including the Phase 3 trial of Annamycin for treating acute myeloid leukemia. The transaction is expected to close on December 11, 2025, pending customary conditions.
Read more →MBRX▼ -8.6%on this news· ran to -33% by day 1shared move
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
Moleculin Biotech has reported a significant increase in enrollment for its pivotal Phase 2B/3 MIRACLE trial, now at 78% consented subjects. The company anticipates completing treatment for the first 45 subjects by Q1 2026, with the potential for Annamycin to provide a safer and more effective option for AML patients. The trial is on track for its first data unblinding soon.
Read more →MBRX▼ -8.6%on this news· ran to -33% by day 1shared move
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
Moleculin Biotech, Inc. announced an increase in enrollment for its pivotal Phase 3 'MIRACLE' trial, with 78% of the target number now consented, up from 60% reported in November. The study is evaluating Annamycin in combination with cytarabine for adult patients with relapsed or refractory acute myeloid leukemia (AML). The first unblinding of data is expected in Q1 2026, after the treatment of a total of 45 subjects. Despite some early challenges in recruitment due to bed shortages in Europe, the company is optimistic about the trial's progress and Annamycin's potential benefits.
Read more →MBRXMoleculin Announces New Annamycin Collaboration in Brain Tumors
Moleculin Biotech has entered a collaboration with CIC biomaGUNE to conduct preclinical studies on Annamycin for glioblastoma multiforme treatment. This research will assess the efficacy of intra-arterial delivery of Annamycin compared to existing therapies. The collaboration aims to explore Annamycin's potential to overcome delivery challenges in treating aggressive brain tumors.
Read more →MBRX▼ -22%on this news
Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin Biotech, Inc. announced that CEO Walter Klemp will participate in the Virtual Investor Closing Bell Series on December 2, 2025. During the event, he will provide a corporate overview and answer live questions from participants. The company is focused on developing therapies for hard-to-treat tumors and viruses, including its lead program Annamycin for acute myeloid leukemia.
Read more →MBRX▼ -22%on this newsshared move
Moleculin Announces Reverse Stock Split
Moleculin Biotech, Inc. announced a 1-for-25 reverse stock split effective December 1, 2025. This move will reduce the number of outstanding shares from approximately 51.7 million to about 2.1 million. The company continues to advance its clinical programs, particularly Annamycin for treating acute myeloid leukemia, but faces challenges in securing necessary financing for its trials.
Read more →MBRX▼ -6.9%on this news
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech reported that 60% of the first 45 subjects have consented to participate in its pivotal Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). The company anticipates completing treatment for these subjects by Q1 2026, with initial unblinded data expected shortly thereafter. Despite some challenges in recruitment due to bed shortages in Europe, the trial is progressing as planned.
Read more →MBRX▼ -6.9%on this newsshared move
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech reports that 60% of the first 45 subjects have consented to participate in its pivotal Phase 2B/3 "MIRACLE" trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). The company anticipates completing treatment by Q1 2026, with initial unblinded data expected shortly thereafter. Despite some site-specific challenges, recruitment momentum remains strong.
Read more →MBRXMoleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Moleculin Biotech has partnered with UNC-Chapel Hill to conduct preclinical research on Annamycin for pancreatic cancer treatment. This collaboration aims to evaluate the drug's effectiveness alongside novel agents. Annamycin has shown a high affinity for pancreatic cancer cells, and the research is part of a broader strategy to explore its clinical applications. The company is also pursuing funding to support its clinical trials.
Read more →MBRX▼ -5.8%on this news
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
Moleculin Biotech, Inc. will present its ongoing Phase 3 MIRACLE trial at the 14th Annual Acute Leukemia Meeting. The trial evaluates Annamycin in combination with cytarabine for adult patients with relapsed or refractory acute myeloid leukemia. Annamycin has received FDA Fast Track Status and Orphan Drug Designation, indicating its potential in treating this challenging condition.
Read more →MBRX▼ -5.8%on this newsshared move
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
Moleculin Biotech, Inc. will present its ongoing Phase 3 'MIRACLE' clinical trial at the 14th Annual Acute Leukemia Meeting. The trial evaluates Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia. The company has received Fast Track and Orphan Drug Designations for Annamycin, highlighting its potential in addressing this challenging condition.
Read more →MBRXMoleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
Moleculin Biotech has been granted an Australian patent for Annamycin, enhancing its global IP portfolio. This patent covers preliposomal Annamycin lyophilizates, which exhibit improved stability and purity. The drug candidate is being developed for treating acute myeloid leukemia and soft tissue sarcoma lung metastases, with ongoing clinical trials showing promising results.
Read more →MBRX▲ +9.8%on this news
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Moleculin Biotech has announced a partnership with Atlantic Health to conduct an investigator-initiated Phase 1B/2 study of Annamycin for treating advanced pancreatic cancer. Annamycin has demonstrated potential in preclinical studies for targeting factors linked to this high-mortality disease. Despite its promise, the company faces challenges such as financing requirements and the inherent risks associated with clinical trial timelines. This study aims to provide a new treatment option where current therapies have limited efficacy.
Read more →MBRXMoleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
Moleculin Biotech announced a notice of allowance for a Canadian patent covering Annamycin, a drug candidate for treating acute myeloid leukemia and soft tissue sarcoma lung metastases. The patent will protect methods for creating a stable preliposomal Annamycin formulation. This development strengthens Moleculin's intellectual property portfolio as they advance Annamycin's clinical trials.
Read more →MBRXMoleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Moleculin Biotech is actively recruiting for its Phase 3 'MIRACLE' trial for Annamycin in treating acute myeloid leukemia. The company has expanded its recruitment sites to include several European countries and the US, aiming to treat 20 subjects by the end of September. They expect to reach 45 patients by Q4 2025 for initial data unblinding, with further expansions planned.
Read more →MBRXMoleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Moleculin Biotech, Inc. is accelerating recruitment for its Phase 3 "MIRACLE" clinical trial of Annamycin for relapsed or refractory acute myeloid leukemia. The company aims to recruit a total of 45 patients by Q4 2025, having already enrolled 13 subjects. The trial is expanding its site locations across Europe and is on track for early data unblinding. Alongside positive operational news, the company is aware of the financial challenges ahead as it seeks additional funding to support the study.
Read more →MBRXMoleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Moleculin Biotech has commenced its pivotal Phase 3 MIRACLE trial for treating acute myeloid leukemia (AML) in the EU, enrolling its first two patients. The trial aims to recruit 45 subjects by the end of 2025, with initial data expected to be unblinded in the second half of 2025. Annamycin, the lead drug, has received regulatory designations to expedite its development.
Read more →MBRX▼ -35.3%on this news
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
Moleculin Biotech has announced the exercise of warrants that will yield approximately $6.0 million in gross proceeds. The company will issue new warrants for additional shares, contingent on shareholder approval. This funding is intended for working capital and corporate purposes. Moleculin is advancing its lead drug, Annamycin, in a Phase 3 trial for AML.
Read more →MBRX▲ +11.3%on this news· ran to -31% by day 3shared move
Moleculin Issues New Positive AML Overall Survival Data:
Moleculin Biotech announced promising results from its Phase 1B/2 trial of Annamycin for acute myeloid leukemia (AML), showing median overall survival rates significantly above industry standards. The trial reported a 36% complete remission rate among subjects, with no observed cardiotoxicity. The company is progressing with its Phase 3 MIRACLE trial and anticipates a clinical study report in early 2026.
Read more →MBRXMoleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Moleculin Biotech, Inc. will present at the Webull Financial Corporate Connect Webinar Series on August 20, 2025. The presentation will be led by CEO Walter Klemp and will highlight the company's advancements in treating hard-to-treat tumors and viruses, particularly focusing on their lead program, Annamycin. The company is currently conducting a Phase 3 trial for Annamycin in acute myeloid leukemia.
Read more →MBRXMoleculin Reports Second Quarter 2025 Financial Results and Highlights
Moleculin Biotech, Inc. (MBRX) has reported its financial results for Q2 2025, highlighting significant progress in its MIRACLE trial for Annamycin, with expansions into multiple countries. The company anticipates the data readout from MIRACLE Part A before the end of 2025. Notably, encouraging results from a Phase 1B/2 trial for soft tissue sarcoma lung metastases have been achieved. However, the company is cautious due to pending regulatory requirements for its EU trial's next stages.
Read more →MBRXMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Moleculin Biotech, Inc. announced promising preclinical data for Annamycin, showcasing its efficacy against various liver cancers, including hepatocellular carcinoma and colorectal liver metastases. This data was presented by Dr. Waldemar Priebe at the Shelby-Lavine Pancreatic Cancer Symposium and indicates significant tumor reduction and improved survival rates in animal models. Notably, Annamycin exhibits targeted accumulation in the liver, offering potential advantages over traditional treatments like doxorubicin, particularly due to its low cardiotoxicity. The results position Annamycin as a strong candidate for further development in treating challenging oncology indications.
Read more →MBRXMoleculin Receives Notice of Intent to Grant New European Patent for Annamycin
Moleculin Biotech, Inc. has announced that it received a Notice of Intent to Grant for a new European patent related to its drug candidate Annamycin. This patent is expected to provide exclusivity in the European Union for Annamycin, which is positioned to be the first non-cardiotoxic anthracycline. The drug is currently under development for treating acute myeloid leukemia and soft tissue sarcoma lung metastases, with additional potential for various cancer types. Walter Klemp, the CEO, emphasized the patent's role in validating Annamycin's potential and enhancing the company's intellectual property portfolio.
Read more →MBRXMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Moleculin Biotech, Inc. participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference, where CEO Walter Klemp shared insights about his commitment to the company and its development programs. The on-demand video is available on the company's website. Moleculin is advancing its lead program, Annamycin, for treating relapsed or refractory acute myeloid leukemia and is also developing other therapeutic candidates.
Read more →MBRXMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Moleculin Biotech, Inc. announced the participation of Walter Klemp in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. In the webcast, Klemp shared insights into his journey and the company's dedication to its therapeutic programs. The company is advancing a pipeline that includes the next-generation anthracycline, Annamycin, aimed at treating acute myeloid leukemia and soft tissue sarcomas. The on-demand video format enhances accessibility for investors and stakeholders.
Read more →MBRX▲ +30.6%on this newsshared move
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. has appointed Adriano Treve as a Strategic Advisor to explore partnerships, leveraging his 40 years of experience at Roche. Treve's expertise is expected to significantly aid Moleculin in achieving strategic partnerships and advancing clinical trials for its candidate Annamycin, particularly in treating acute myeloid leukemia. The company anticipates unblinding data for the MIRACLE trial, which may lead to an increase in interest from potential partners. However, Moleculin also faces challenges, including the need for additional financing to support ongoing trials.
Read more →MBRX▲ +9.7%on this news· ran to +21% by day 3
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Moleculin Biotech has secured approval for its Phase 2B/3 MIRACLE trial from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia. This follows a recent approval from the European Medicines Agency (EMA) and aims to treat adult patients with relapsed or refractory acute myeloid leukemia (AML). The trial expects to recruit over 30 clinical sites across Europe and the US by year-end, with an anticipated data readout in the second half of 2025. Enrollment has begun with seven subjects treated and one additional subject in screening.
Read more →MBRX▼ -54.2%on this news
Moleculin Announces $5.9 Million Public Offering
Moleculin Biotech, Inc. has announced a public offering of 16,080,000 shares of common stock and Series E warrants, expected to raise around $5.9 million. The offering is set to close on June 23, 2025, subject to customary conditions. The proceeds will be utilized to further the development of their lead program, Annamycin, and other therapeutic candidates, as well as for general working capital. This move comes after preliminary success with the drug in previous clinical trials, including a pivotal Phase 3 study for acute myeloid leukemia.
Read more →MBRX▼ -12.5%on this news· ran to -60% by day 1shared move
Moleculin Participates in Virtual Investor “What This Means” Segment
Moleculin Biotech participated in a Virtual Investor segment discussing its positive FDA feedback on the Pediatric Study Plan for Annamycin, a drug targeting relapsed/refractory acute myeloid leukemia. The company is advancing its Phase 3 trial for Annamycin and has reported its design to avoid cardiotoxicity. However, it faces challenges in securing necessary financing for ongoing clinical trials.
Read more →MBRX▼ -12.5%on this news· ran to -60% by day 1shared move
Moleculin Participates in Virtual Investor “What This Means” Segment
Moleculin Biotech, Inc. participated in a Virtual Investor segment discussing positive FDA feedback on the Pediatric Study Plan for Annamycin, an anthracycline treatment for relapsed/refractory acute myeloid leukemia. The company's lead program aims to minimize cardiotoxicity while effectively treating hard-to-treat tumors and viruses. Moleculin is also advancing its Phase 3 MIRACLE trial evaluating Annamycin's effectiveness in combination with cytarabine. However, the company highlights the need for significant additional funding to support its clinical trials and future milestones.
Read more →MBRX▼ -12.5%on this news· ran to -60% by day 1shared move
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Moleculin Biotech has announced that the FDA approved its Initial Pediatric Study Plan (iPSP) for Annamycin, indicating that patients as young as 6 months can participate in the pediatric study for relapsed/refractory acute myeloid leukemia (R/R AML). Annamycin, which has shown no cardiotoxicity in adult trials, aims to provide a safer treatment option for children. The pediatric clinical study is expected to begin in the second half of 2027 as Moleculin updates its iPSP in line with FDA recommendations. The company also continues its pivotal Phase 3 MIRACLE trial for adults with R/R AML, with initial data readout anticipated in late 2025.
Read more →MBRXMoleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Moleculin Biotech has released an on-demand webcast reviewing data from its Phase 1B/2 trial for Annamycin, aimed at treating soft tissue sarcoma lung metastases. The event features industry leaders discussing the therapy's potential, emphasizing its ability to mitigate common cardiotoxicity associated with traditional treatments. Furthermore, the company is pursuing a Phase 3 trial for Annamycin in combination therapy for acute myeloid leukemia, but highlights include necessary future regulatory filings and significant funding challenges that could impact its development timeline.
Read more →MBRX▼ -19.8%on this newsshared move
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Moleculin Biotech, Inc. announced favorable topline results from its Phase 1B/2 trial of Annamycin, aimed at treating soft tissue sarcoma lung metastases (STS lung mets). The trial showed a Clinical Benefit Rate of 59.4%, with notable improvements in both overall survival and progression-free survival among subjects. The findings suggest Annamycin could offer a viable treatment option, especially for patients who have undergone multiple previous chemotherapy regimens. Additionally, the absence of cardiotoxicity enhances the drug's appeal as a therapeutic agent in this challenging cancer indication.
Read more →MBRX▼ -7.2%on this news
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
Moleculin Biotech has reported its financial results for Q1 2025 and provided updates on its clinical trials, notably the ongoing Phase 3 MIRACLE trial for Annamycin in treating relapsed/refractory acute myeloid leukemia (R/R AML). The recent approval from the European Medicines Agency (EMA) allows the trial to proceed in nine additional EU countries, bolstering the company’s operational momentum. Patient dosing is now active, and the first data readout is expected in the second half of 2025. Progress has also been noted in other pipeline developments, reinforcing the company's optimistic outlook.
Read more →MBRXMoleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Moleculin Biotech has received approval from the European Medicines Agency to expand its Phase 3 MIRACLE clinical trial for Annamycin into nine EU countries. This approval aims to recruit adult patients with relapsed or refractory acute myeloid leukemia, particularly those who have shown poor outcomes with existing therapies. The trial is expected to improve recruitment capabilities while providing critical data on Annamycin's efficacy and safety. Initial results from the trial are anticipated in the second half of 2025.
Read more →MBRXMoleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
Moleculin Biotech, Inc. announced it will report its first quarter financial results for 2025 on May 13, 2025, followed by a conference call to discuss the results on May 14, 2025. The company continues to develop innovative therapies for challenging cancers, particularly its lead candidate Annamycin, which has shown promise in past clinical trials. However, it requires substantial additional financing to proceed with its clinical trials, which introduces a level of uncertainty regarding its future operations.
Read more →MBRXMoleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
Moleculin Biotech announced that the World Health Organization approved 'naxtarubicin' as the International Non-Proprietary Name for Annamycin, a next-generation anthracycline. This drug is currently in a pivotal Phase 3 trial for treating relapsed or refractory acute myeloid leukemia. The company anticipates interim data from the trial in the second half of 2025.
Read more →MBRXMoleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
Moleculin Biotech, Inc. announced that the World Health Organization has approved the non-proprietary name 'naxtarubicin' for its drug Annamycin, which is currently being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma. This approval is seen as a significant step towards the potential commercialization of Annamycin. The ongoing Phase 3 clinical trial, named MIRACLE, is designed to assess Annamycin's efficacy, with initial data expected in late 2025. The drug is recognized for its potential safety and effectiveness compared to existing anthracyclines used in oncology.
Read more →MBRXMoleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
Moleculin Biotech has announced the granting of two new U.S. patents covering Annamycin, expanding its intellectual property rights until June 2040. These patents relate to methods for making liposomal Annamycin, enhancing the drug's potential in treating various cancers, including acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also advancing its Phase 3 MIRACLE trial and expects to report initial data in the latter half of 2025. However, financing remains a challenge as further clinical development depends on timely funding.
Read more →MBRXMoleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Moleculin Biotech has announced promising pre-clinical data for Annamycin, presented at the AACR Annual Meeting 2025. The data suggests that Annamycin may effectively target not only hematological malignancies but also solid tumors, including pancreatic cancer, demonstrating its potential for market expansion. The drug appears to enhance the effectiveness of several approved cancer therapies when used in combination. Moleculin plans to initiate further clinical trials to explore these new applications of Annamycin, with a focus on overcoming challenges posed by treatment-resistant cancers.
Read more →MBRXMoleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Moleculin Biotech, Inc. announced that an abstract concerning its next-generation anthracycline, Annamycin, has been accepted for presentation at the AACR Annual Meeting 2025. The presentation will focus on combining Annamycin with other drugs to enhance anticancer effects. Annamycin is currently being developed for the treatment of relapsed or refractory acute myeloid leukemia. The company is preparing for a pivotal Phase 3 trial, which follows positive results from earlier studies.
Read more →MBRXMoleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Moleculin Biotech has initiated the dosing of the first patient in its Phase 3 MIRACLE trial, evaluating Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (AML). The study is designed to unblind preliminary data in the second half of 2025, providing critical insights into the efficacy of the treatment. Annamycin has already received Fast Track and Orphan Drug designations from the FDA. However, the company must secure additional financing to proceed with the trial as planned.
Read more →MBRXMoleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
Moleculin Biotech, Inc. recently reported its financial results for 2024, highlighting progress in its Phase 3 MIRACLE trial aimed at treating relapsed or refractory acute myeloid leukemia (AML). The company is on track to begin treatment of its first subject in early 2025, with the initial data readout expected in the second half of the same year. Additionally, they have received favorable FDA guidance and expanded patent protections for Annamycin. Moleculin remains optimistic about upcoming milestones that could enhance the development of its therapies.
Read more →MBRXMoleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
Moleculin Biotech, Inc. will report its full year 2024 financial results on March 21, 2025, followed by a conference call on March 24, 2025, to discuss the findings. The Company is advancing several drug candidates, with Annamycin in development for treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. A pivotal Phase 3 trial for Annamycin is set to begin, alongside ongoing work on other therapeutic drug candidates.
Read more →MBRX▲ +5.3%on this news
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Moleculin Biotech, Inc. participated in the Virtual Investor "Top 5 for '25" On-Demand Conference, where CEO Walter Klemp presented compelling reasons for investment in the company. The firm is advancing its lead program, Annamycin, in a pivotal Phase 3 trial for relapsed or refractory acute myeloid leukemia. The company is also developing additional therapies targeting various cancers and viruses.
Read more →MBRXMoleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
Moleculin Biotech, Inc. participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO Walter Klemp highlighted key reasons for investment interest in 2025. The company is advancing its lead program, Annamycin, through a pivotal Phase 3 trial for AML. The firm aims to address hard-to-treat tumors and has received positive FDA input on its development pathway.
Read more →MBRXMoleculin to Present at the 37th Annual ROTH Conference
Moleculin Biotech, Inc. announced that its CEO, Walter Klemp, will participate in a fireside chat at the 37th Annual ROTH Conference on March 18, 2025. The company, known for its late-stage drug candidates targeting hard-to-treat tumors, will also hold one-on-one meetings with investors. Annamycin, their lead program, is in Phase 3 trials for AML and STS lung metastases.
Read more →MBRX▼ -5.2%on this newsshared move
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
Moleculin Biotech announced the receipt of a Notice of Intent to Grant for a European patent on Annamycin, enhancing its global exclusivity. The company anticipates an initial data readout from the Phase 3 MIRACLE trial in the second half of 2025. Annamycin is being developed as a non-cardiotoxic treatment for acute myeloid leukemia and other cancers.
Read more →MBRX▼ -10.9%on this newsshared move
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Moleculin Biotech, Inc. announced that its abstract has been accepted for a poster presentation at the Acute Leukemias XIX International Symposium in Munich, Germany, scheduled for March 16-19, 2025. The presentation will focus on the use of Liposomal Annamycin in combination with Cytarabine for treating Acute Myeloid Leukemia. This follows the company's successful Phase 1B/2 study, indicating a positive trajectory towards potential FDA approval.
Read more →MBRX▼ -13.7%on this news
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
Moleculin Biotech, Inc. has announced a $3.5 million registered direct offering and concurrent private placement to support its operations. The offering involves the sale of shares and warrants, with proceeds aimed at working capital. The company is advancing its lead drug, Annamycin, through a pivotal Phase 3 trial for treating relapsed or refractory acute myeloid leukemia.
Read more →MBRX▼ -55.7%on this news
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
Moleculin Biotech, Inc. has announced the exercise of warrants for approximately $5.8 million in gross proceeds. The company will issue new warrants at a reduced price of $0.75 per share, which will be immediately exercisable. The funds will be used for working capital and corporate purposes, with the transaction expected to close on February 14, 2025.
Read more →MBRX▲ +202.4%on this news· ran to +419% by day 1shared move
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Moleculin Biotech has received positive FDA guidance for its Phase 3 MIRACLE trial evaluating Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia. The FDA's feedback allows for a 10% reduction in trial size, supporting an accelerated timeline for drug approval. The trial aims to demonstrate Annamycin's efficacy while avoiding cardiotoxicity, a significant advancement in cancer treatment.
Read more →MBRX▼ -27.9%on this news· ran to +210% by day 3shared move
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
Moleculin Biotech has received its first regulatory approval in Europe to begin recruiting for the MIRACLE Phase 3 trial, evaluating Annamycin combined with Cytarabine for R/R AML patients. The trial aims to treat patients and is expected to start in early 2025, with preliminary efficacy data anticipated in the second half of 2025. The company is also focused on expanding site recruitment across multiple regions.
Read more →MBRXMoleculin Participates in Virtual Investor "What This Means" Segment
Moleculin Biotech's CEO, Walter Klemp, provided an update on the Phase 3 MIRACLE trial for Annamycin, aimed at treating relapsed or refractory acute myeloid leukemia (AML). The trial will be global, involving sites in the US, Europe, and the Middle East. The company believes it has de-risked the approval pathway following a successful Phase 1B/2 study.
Read more →MBRXMoleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Moleculin Biotech has received IRB approval for its Phase 3 MIRACLE trial of Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML). The trial is set to begin dosing in Q1 2025, with preliminary results expected in late 2025 and early 2026. Annamycin has demonstrated a 60% complete response rate in preliminary results, significantly outperforming historical data.
Read more →MBRX▲ +14.7%on this news
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Biotech announced the online publication of preclinical data for Annamycin, highlighting its effectiveness against venetoclax-resistant acute myeloid leukemia (AML) cell lines. The study demonstrates that Annamycin, a non-cardiotoxic anthracycline, exhibited significant activity and synergy when combined with Cytarabine (Ara-C), as evidenced by a 60% complete remission rate in resistant patients. The research, shared at the ASH Annual Meeting, suggests that Annamycin could provide a new treatment option for patients with limited options. The upcoming Phase 3 MIRACLE trial aims to further assess the effectiveness of Annamycin in this context.
Read more →MBRX▼ -7%on this news
New Findings Show Moleculin’s Annamycin Overcomes Resistance to Venetoclax in AML
Moleculin Biotech announced promising findings for Annamycin in overcoming resistance to Venetoclax in AML. New clinical data revealed a 60% complete response rate in patients previously treated with Venetoclax. The upcoming ASH Annual Meeting will feature further details, including an abstract on Annamycin's efficacy. The company plans to initiate a pivotal Phase 3 trial in early 2025.
Read more →MBRX▼ -7%on this newsshared move
New Findings Show Moleculin
Moleculin Biotech announced promising new findings regarding their drug Annamycin, specifically addressing its efficacy against Venetoclax-resistant acute myeloid leukemia (AML). Preliminary clinical data indicate a 60% complete response rate when Annamycin is combined with Ara-C, a significant improvement over past treatment outcomes. Additionally, the company is moving forward with the Phase 3 MIRACLE trial aimed at these hard-to-treat patients, with hopes for approval as early as 2025.
Read more →MBRX▲ +23.1%on this newsshared move
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin Biotech, Inc. has amended its clinical trial protocol for the MIRACLE Phase 3 trial targeting relapsed or refractory acute myeloid leukemia (AML). This amendment permits the accelerated unblinding of primary efficacy and safety data at 45 subjects, with expectations set for the unblinding process to yield results by the second half of 2025. The trial aims to evaluate the effectiveness of Annamycin combined with Cytarabine and aims to gather definitive data that could facilitate strategic partnerships and potential drug approvals.
Read more →MBRX▲ +5.2%on this newsshared move
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Moleculin Biotech has obtained Institutional Review Board approval for its pivotal Phase 3 trial, named MIRACLE, investigating Annamycin combined with cytarabine for patients with relapsed or refractory acute myeloid leukemia (AML). The trial aims for potential accelerated approval and plans to commence enrollment in early 2025. Annamycin currently holds Fast Track Status and Orphan Drug Designation from the FDA for AML treatment, enhancing its development prospects. The trial's design involves adaptive strategies to optimize dosing based on safety and efficacy evaluations, underlining the company’s commitment to addressing unmet medical needs in AML.
Read more →MBRXMoleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Moleculin Biotech, Inc. reported its financial results for Q3 2024, highlighting positive updates regarding its lead program, Annamycin. The company is set to initiate a pivotal Phase 3 trial known as the MIRACLE trial in early 2025, targeting relapsed or refractory acute myeloid leukemia (AML). Additionally, the median duration of complete response composite in the ongoing AML clinical trial has exceeded 8 months. Moleculin's preparations and recent regulatory discussions are positioned to enhance the drug's prospects in the treatment landscape.
Read more →MBRXMoleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its financial results for Q3 2024 on November 8, 2024. A conference call and webcast are scheduled for November 11 to discuss these results. The company is advancing its lead program Annamycin for treating relapsed or refractory acute myeloid leukemia, and initiating the pivotal MIRACLE trial for further evaluation. Moleculin also focuses on developing therapies targeting brain tumors, pancreatic cancer, and other indications in its pipeline.
Read more →MBRXMoleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech, Inc. has appointed Dr. Daniel D. Von Hoff to its Annamycin Scientific Advisory Board, enhancing the team's expertise in the treatment of pancreatic cancer. Annamycin is currently under investigation for its potential effects against aggressive cancers such as acute myeloid leukemia and soft tissue sarcoma. Recent findings presented at the AACR highlight Annamycin's ability to target and accumulate in the pancreas, suggesting its applicability in treating pancreatic cancer. The company is moving forward with the MIRACLE trial and has received special designations from the FDA and EMA, positioning it well for future development.
Read more →MBRXTranscript from Moleculin’s Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
Moleculin Biotech has made the transcript of its recent Virtual Acute Myeloid Leukemia KOL event available. The event featured discussions on Annamycin, a drug that could significantly impact AML treatment. The company is advancing its Phase 3 MIRACLE trial for relapsed or refractory AML patients, bolstered by positive preliminary data.
Read more →MBRXTranscript from Moleculin
Moleculin Biotech, Inc. has made the transcript from its recent Virtual Acute Myeloid Leukemia KOL event available online. The event highlighted the potential of Annamycin, a next-generation anthracycline drug, in changing the treatment landscape for AML. Notable experts attended the event, discussing Annamycin's use and the upcoming Phase 3 MIRACLE trial, aimed at treating patients with relapsed or refractory AML. Moleculin expresses confidence in Annamycin's capacity to meet unmet medical needs based on encouraging preliminary data.
Read more →MBRX▲ +6.4%on this news
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
Moleculin Biotech, Inc. announced it will host a virtual Key Opinion Leader (KOL) event focused on Acute Myeloid Leukemia (AML) on October 14, 2024. This event will feature discussions led by prominent experts, including Moleculin's management team, about the potential of its drug Annamycin and the ongoing MIRACLE trial aimed at treating relapsed or refractory AML. The company's focus is on developing therapies that address hard-to-treat tumors, with Annamycin being designed to mitigate common side effects of existing treatments.
Read more →MBRXMoleculin to Present at Two Upcoming Investor Conferences
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced its participation in two upcoming investor conferences, enhancing its engagement with the investor community. The first event is the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, where the focus will be on innovative therapies for liquid tumors. The second is the 2024 Healthcare Virtual Summit on October 16, 2024, featuring a fireside chat format. This visibility is particularly noteworthy given the Company's efforts in advancing its lead program, Annamycin, which targets relapsed AML and STS lung metastases.
Read more →MBRX▲ +14.3%on this news
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
Moleculin Biotech, Inc. revealed positive in vivo efficacy data for Annamycin at the IASLC 2024 World Conference on Lung Cancer. The data indicate significant tumor growth inhibition and increased survival in lung cancer models, along with a notable absence of cardiotoxicity. Annamycin is being assessed in clinical trials for treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases and has received Fast Track Status and Orphan Drug Designation from the FDA.
Read more →MBRXMoleculin Participates in Virtual Investor “What this Means” Segment
Moleculin Biotech, Inc. CEO Wally Klemp participated in a virtual investor segment discussing the Phase 2 clinical trial of WP1066 combined with radiation for glioblastoma treatment. The trial is under an IND application cleared by the FDA and funded by NIH and BrainUp. The company is also advancing its lead program, Annamycin, for AML and STS lung metastases.
Read more →MBRXMoleculin Participates in Virtual Investor "What this Means" Segment
Moleculin Biotech, Inc. announced CEO Wally Klemp's participation in a Virtual Investor segment discussing the company's Phase 2 clinical trial of the STAT3 inhibitor WP1066 combined with radiation therapy for glioblastoma. The trial, funded by the NIH and endorsed by BrainUp®, utilizes an IND that received FDA clearance in April 2022. Moleculin's diverse therapeutic pipeline also includes promising candidates like Annamycin for acute myeloid leukemia and antimetabolites targeting various cancers and viruses.
Read more →MBRXMoleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
Moleculin Biotech has announced the first patient enrollments in a Phase 2 clinical trial for WP1066 in combination with radiation therapy targeting glioblastoma. This investigator-initiated study at Northwestern University is a critical next step in developing therapies for this challenging cancer type. Notably, the trial is supported by funding from the NIH and BrainUp, and early preclinical results have indicated potential for improved patient survival rates. The trial specifically targets newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma patients.
Read more →MBRXMoleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Moleculin Biotech, Inc. announced that CEO Walter Klemp will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. The company emphasizes the importance of this conference for engaging with investors and building relationships. A video webcast will be available for registered attendees post-event. Moleculin's lead candidate, Annamycin, is in development for treating severe cancers, with a pivotal Phase 3 trial set to advance its potential approval.
Read more →MBRX▲ +6.7%on this news
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Moleculin Biotech, Inc. announced that its CEO, Walter Klemp, will present at the LIVE! with Webull Corporate Connect Healthcare Investment Webinar on August 28, 2024. The presentation will focus on the company's progress in advancing its drug candidates targeting difficult-to-treat tumors and viruses. Notably, Moleculin is embarking on a Phase 3 clinical trial for its lead program, Annamycin, for treating relapsed or refractory acute myeloid leukemia. This event reflects the growing interest and potential of Moleculin in the biopharma sector.
Read more →MBRXMoleculin Announces Closing of up to $16.5 Million Public Offering
Moleculin Biotech, Inc. has completed a public offering of up to $16.5 million, consisting of 2,466,368 shares of common stock and associated warrants. The initial proceeds amount to $5.5 million, with the potential for an additional $11 million if the warrants are fully exercised. The company plans to utilize the funds to advance its clinical programs, notably Annamycin for treating acute myeloid leukemia and soft tissue sarcoma. Shareholder approval will be required for certain warrant exercises, adding an element of risk in realizing the full potential of the raised capital.
Read more →MBRX▲ +9.4%on this newsshared move
Moleculin Announces Pricing of up to $16.5 Million Public Offering
Moleculin Biotech, Inc. has announced a public offering of 2,466,368 shares, aiming to raise up to $16.5 million. The offering includes Series A and B warrants linked to further capital based on milestone achievements. The proceeds will primarily fund the advancement of its clinical programs, including Annamycin for treating difficult cancers like acute myeloid leukemia. The closing of the offering is anticipated around August 19, 2024, pending standard conditions.
Read more →MBRX▲ +6.4%on this newsshared move
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Moleculin Biotech, Inc. reported promising developments in its clinical trial for Annamycin, with a positive outcome from its End of Phase 1B/2 meeting with the FDA. The company is now advancing towards a pivotal Phase 3 trial, known as the MIRACLE trial, for Annamycin in combination with cytarabine to treat relapsed or refractory acute myeloid leukemia (R/R AML). Financial results indicated a slight increase in R&D expenses, and the company has announced plans to raise additional funds to ensure operational continuity into 2025. Overall, the ongoing trials and regulatory feedback position Moleculin well for the upcoming stages of their drug development.
Read more →MBRX▼ -6.9%on this news
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET
Moleculin Biotech, Inc. has announced a webcast presentation scheduled for August 6, 2024, to discuss its plans for a Phase 3 pivotal trial of Annamycin in combination with Cytarabine, targeting relapsed or refractory acute myeloid leukemia (AML) patients. The trial, named the MIRACLE trial, will take place globally, including sites in the US. This development follows a successful Phase 1B/2 study, which has provided the company with considerable confidence as they move forward. The webcast will feature key company executives and an expert from MD Anderson Cancer Center.
Read more →MBRX▼ -27.9%on this newsshared move
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
Moleculin Biotech announced plans to initiate a Phase 3 clinical trial, dubbed the MIRACLE trial, for its drug Annamycin in combination with cytarabine (Ara-C) for treating relapsed or refractory acute myeloid leukemia (AML) after encouraging discussions with the FDA. The trial's design will utilize an adaptive approach to optimize dosing and aims to provide evidence for accelerated approval based on complete remission rates. The company anticipates starting patient enrollment in 2025 and has established significant milestones leading up to potential drug application submissions in 2028.
Read more →MBRXMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech, Inc. has announced the completion of its End of Phase 2 meeting with the FDA regarding Annamycin for acute myeloid leukemia (AML). The meeting discussed safety and efficacy findings and next steps for the clinical development program. The company expects to report outcomes from the meeting by the end of Q3 2024. Preliminary results from the ongoing MB-106 clinical trial showed promising efficacy, with a substantial number of subjects achieving complete remission.
Read more →MBRXMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
Moleculin Biotech, Inc. announced positive preliminary interim data from its Phase 1B/2 clinical trial of Annamycin in combination with Cytarabine for acute myeloid leukemia (AML). The trial demonstrated a median durability of response of 6 months for patients achieving complete remission, with notable results in subjects having poor prognosis cytogenetics. Annamycin continues to show promise as a treatment with no significant cardiotoxicity reported. The findings were presented at the European Hematology Association Congress, further highlighting the potential of Annamycin in addressing unmet needs in AML.
Read more →MBRXMoleculin to Present at the Virtual Investor Pitch Conference
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced its participation in the Virtual Investor Pitch Conference on June 18, 2024. CEO Walter Klemp will deliver a presentation highlighting upcoming milestones and answer investor questions. The event will include a live webcast accessible on the company's website, with a replay available afterward. Moleculin's portfolio comprises promising therapies targeting challenging tumors and viruses.
Read more →MBRX▲ +7.9%on this news
Moleculin to Participate in the Virtual Investor Lunch Break Series
Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced its participation in the Virtual Investor Lunch Break: The Moleculin Opportunity event scheduled for June 12, 2024. Walter Klemp, the company's CEO, will provide a corporate overview and business outlook, allowing investors to ask questions during the event. This engagement emphasizes the company's commitment to transparency and communication with stakeholders regarding its ongoing clinical programs and pipeline.
Read more →MBRXMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Biotech, Inc. announced that its abstract has been accepted for a poster presentation at the European Hematology Association (EHA) 2024 Hybrid Congress. The presentation will focus on the use of LIPOSOMAL ANNAMYCIN in combination with cytarabine for treating patients with acute myeloid leukemia who are refractory or relapsed after induction therapy. The event will take place from June 13-16, 2024, in Madrid, Spain, and virtually. This recognition of their research highlights Moleculin's advancements in developing novel treatments for difficult-to-treat tumors.
Read more →MBRXMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
Moleculin Biotech, Inc. has announced the initiation of an Investigator-Initiated Phase 2 clinical trial to evaluate its STAT3 inhibitor, WP1066, in conjunction with radiation therapy for glioblastoma patients. The trial, conducted at Northwestern University, aims to address the significant unmet medical need in treating this aggressive brain tumor. Funded by the National Institutes of Health (NIH), this study will assess the drug's efficacy based on progression-free survival among newly diagnosed patients. Preliminary data indicated encouraging responses in preclinical models, bolstering the potential for WP1066 as a viable treatment option.
Read more →MBRXMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
Moleculin Biotech reported encouraging first quarter 2024 results, focusing on the Annamycin drug's performance in AML treatment. Interim data revealed a combined complete remission composite (CRc) rate of 62% for Annamycin in combination with Ara-C therapy in first and second-line patients. The enrollment of 20 subjects and the issuance of new patents further strengthen the company's position. A conference call is scheduled to provide an in-depth discussion of the results and future plans.
Read more →MBRXMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Moleculin Biotech has announced the upcoming issuance of a U.S. patent on their lipid-based delivery technology for the drug Annamycin, which is designed for treating acute myeloid leukemia (AML). This patent, expected to be granted on May 14, 2024, will provide composition protection until 2040, contributing to the company's intellectual property portfolio. Annamycin is showing potential in clinical trials, particularly a recent study demonstrating a 60% composite complete response rate in advanced AML cases. The company aims to leverage this patent for potential future partnerships and expanded clinical development.
Read more →MBRX▼ -7.7%on this newsshared move
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
Moleculin Biotech, Inc. will announce its financial results for Q1 2024 on May 10, 2024. Management will also host a conference call and webcast on May 13, 2024, to discuss these results. The company continues to focus on developing treatments for hard-to-treat tumors and viruses, with several pipeline candidates currently in development. Notably, their lead program Annamycin aims to treat acute myeloid leukemia and soft tissue sarcoma.
Read more →MBRXMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Moleculin Biotech, Inc. has announced positive interim data regarding Annamycin's effectiveness in treating acute myeloid leukemia (AML). The reported complete remission rate (CRc) for the combination of Annamycin and Cytarabine is 62% among 1st and 2nd line AML subjects, with a median durability of remission at 4.9 months. The company is preparing to advance to a Phase 2 registration-directed clinical trial to gather further data to support an eventual New Drug Approval (NDA) application. Additionally, a virtual Clinical Day with key clinicians was scheduled to discuss these findings.
Read more →MBRXMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Moleculin Biotech, Inc. is organizing a virtual AML Clinical Day on May 7, 2024, featuring Dr. Martin S. Tallman, a notable expert in leukemia treatment. The session will address the company's developments with Annamycin, a drug aiming to meet significant unmet medical needs in acute myeloid leukemia (AML), and will review its clinical development program. Attendees can expect insights into Annamycin's data thus far and the broader landscape of AML treatments.
Read more →MBRXMoleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech, Inc. has announced the creation of a Scientific Advisory Board to accelerate the development of its drug Annamycin, with Dr. Martin Tallman appointed as the inaugural member. Dr. Tallman, a notable figure in leukemia treatment, aims to guide the advancement of Annamycin, which currently has received Fast Track and Orphan Drug Designation for specific cancer indications. The company highlights ongoing positive data from Annamycin's clinical programs, intending to progress towards pivotal studies in acute myeloid leukemia (AML). This strategic move is seen as a significant step in addressing unmet medical needs in oncology.
Read more →MBRX▲ +5.7%on this news
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin’s Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech's Annamycin has received Orphan Drug Designation from the EMA for treating acute myeloid leukemia (AML). The drug has demonstrated a 60% composite complete response rate in a European clinical trial, with no cardiotoxicity observed. Moleculin plans to initiate a pivotal study for Annamycin as a second-line therapy in AML by the end of 2024.
Read more →MBRX▲ +5.7%on this newsshared move
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin
Moleculin Biotech, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to its next-generation anthracycline, Annamycin, for the treatment of acute myeloid leukemia (AML). Clinical trials have shown promising results, with a preliminary complete response rate of 60% in second-line AML patients. Annamycin has a lower toxicity profile than traditional anthracyclines, having shown no cardiotoxicity. The company plans to advance Annamycin toward a pivotal registration study in late 2024, building on its growing body of clinical data.
Read more →MBRXMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Moleculin Biotech, Inc. announced positive preclinical data for Annamycin, its next-generation anthracycline, highlighting its effectiveness as a potent inhibitor of topoisomerase II-alpha and II-beta without causing cardiotoxicity. Presented at the AACR Annual Meeting, the results indicated that Annamycin did not affect cardiomyocyte viability or contractility in studies with human cells and animal models. This development is particularly significant for treating patients who have traditionally been exposed to cardiotoxic anthracycline therapies. Additionally, Moleculin recently secured patent protection for Annamycin, enhancing its potential for broader clinical applications.
Read more →MBRX▲ +6.7%on this news
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Moleculin Biotech, Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 4, 2024. CEO Walter Klemp will discuss the company's clinical-stage drug candidates targeting challenging tumors and viruses. The event will include one-on-one meetings for investors, and a live webcast will be available on the company's website.
Read more →MBRX▲ +6.7%on this newsshared move
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Moleculin Biotech, Inc. announced that its CEO, Walter Klemp, will present at the MedInvest Biotech & Pharma Investor Conference on April 4, 2024. The conference will take place in New York City, and the company will offer a live webcast of the presentation. Additionally, management will be available for one-on-one meetings with registered investors, highlighting their commitment to engaging with the investment community. Moleculin has a diverse pipeline targeting difficult tumors and viruses, including lead program Annamycin for acute myeloid leukemia and a portfolio of other treatments.
Read more →MBRX▲ +18.4%on this newsshared move
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Moleculin Biotech, Inc. (MBRX) announced participation in the Virtual Investor Lunch Break: The Moleculin Opportunity, scheduled for March 28, 2024. CEO Walter Klemp will discuss the company's corporate overview and future business outlook. The live event will be accessible online, with a replay available for 90 days. Moleculin is focused on developing drug candidates targeting difficult-to-treat tumors and viruses, including its lead program, Annamycin, for AML and soft tissue sarcomas.
Read more →MBRX▲ +18.4%on this newsshared move
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Moleculin Biotech, Inc. announced it will receive a U.S. patent for Annamycin, aimed at treating acute myeloid leukemia (AML) and soft tissue sarcoma metastases. The patent, which offers protection until 2040, is expected to enhance the asset's value and aid in future partnerships. Annamycin demonstrated impressive clinical trial results, achieving a 60% complete response composite rate, exceeding that of existing AML treatments. The patent reinforces Moleculin's innovative lipid-based delivery technology for this next-generation anthracycline.
Read more →MBRX▼ -8%on this newsshared move
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Moleculin Biotech announced positive interim results from its Phase 1B/2 trial evaluating Annamycin in combination with Cytarabine for acute myeloid leukemia (AML) treatment. The combination therapy achieved a complete response composite (CRc) rate of 60% among 2nd line AML patients, indicating potential advantages over existing therapies. The company is preparing for regulatory discussions with the FDA aimed at advancing Annamycin towards pivotal studies expected to initiate in 2024. Continued positive outcomes and interest from key opinion leaders suggest a significant role for Annamycin in addressing unmet needs in AML therapy.
Read more →MBRX▼ -14%on this newsshared move
Moleculin Reports Full Year 2023 Financial Results
Moleculin Biotech, Inc. reported its financial results for the fiscal year 2023, highlighting a significant progress in the clinical trial of its lead drug, Annamycin, for acute myeloid leukemia (AML). The company noted encouraging safety and efficacy data, paving the way for a pivotal study. Despite a net loss of $29.8 million, Moleculin successfully extended its cash runway into late 2024 through a recent funding round. Upcoming events include a conference call with stakeholders to discuss the progress and objectives.
Read more →MBRX▼ -19.7%on this news· ran to -33% by day 3shared move
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
Moleculin Biotech, Inc. has announced it will report its financial results for the year ended December 31, 2023, on March 22, 2024. The company plans to host a conference call and webcast to discuss its clinical, operational, and financial outcomes on March 25, 2024. Moleculin is focusing on the advancement of Annamycin as a treatment for acute myeloid leukemia, as well as developing other drug candidates targeting difficult cancers and viruses.
Read more →MBRXMoleculin to Present at the 36th Annual ROTH Conference
Moleculin Biotech, Inc. (Nasdaq: MBRX) will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024. Jonathan Foster, the Executive VP and CFO, will present, and management will conduct one-on-one meetings with registered attendees. The event will be accessible via a live webcast, which will be archived for 90 days. Moleculin is focused on developing therapies for hard-to-treat tumors and viruses, including its lead candidate, Annamycin.
Read more →MBRX▲ +11.1%on this news
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Moleculin Biotech, Inc. has reported preliminary 2023 data on its Annamycin clinical trials, showing promising response rates for treating acute myeloid leukemia (AML) and soft tissue sarcoma. Key highlights include a 40% complete response rate in AML, with no signs of cardiotoxicity associated with the treatment. The company aims to transition to pivotal Phase 2B/3 trials by the end of 2024, supported by robust patient enrollment and encouraging results. Upcoming milestones include an FDA End of Phase 2 meeting and additional data readouts planned for 2024.
Read more →MBRXMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
Moleculin Biotech, Inc. has announced a $4.5 million direct offering and concurrent private placement, intended to finance their drug development programs. The offering involves 7,044,836 shares of common stock sold at $0.64 per share for a healthcare-focused institutional investor and $0.69 for certain executive officers and directors. The prospects of closing are expected by December 26, 2023, contingent upon standard closing conditions. Maxim Group LLC is serving as the sole placement agent for this transaction.
Read more →MBRXMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
Moleculin Biotech presented positive interim data from its Phase 1B/2 trial of Annamycin for treating acute myeloid leukemia (AML) at the ASH Annual Meeting. The trial reported a 36% complete response rate among intent-to-treat subjects, with durability of responses up to 8 months. Annamycin continues to demonstrate no cardiotoxicity, although two subjects experienced adverse events.
Read more →MBRXMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL
Moleculin Biotech, Inc. presented positive interim findings from its Phase 1B/2 clinical trial evaluating Annamycin for treating acute myeloid leukemia at the recent ASH meeting. The trial showed a 36% complete response rate among all participants and 44% among those treated with Annamycin, with no relapses reported to date. Recruitment for the study has progressed significantly, reaching 59%, and the drug has maintained a 100% non-cardiotoxic profile. Despite a few adverse events, including allergic reactions, the overall results are encouraging for Moleculin's ongoing research into Annamycin's potential as a leukemia treatment.
Read more →MBRXMoleculin Reports Third Quarter 2023 Financial Results
Moleculin Biotech, Inc. reported its financial results for Q3 2023, highlighting a cash balance of $24.6 million sufficient to fund operations into Q3 2024. The third quarter was marked by promising clinical data for Annamycin, its lead program targeting acute myeloid leukemia (AML) and soft tissue sarcoma (STS). The company is making strides towards pivotal studies in 2024, amid ongoing developments and assessments affirming Annamycin's safety. Despite a reported net loss of $5.6 million, the management maintains a positive outlook for the pipeline.
Read more →MBRXMoleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
Moleculin Biotech announced positive interim data from its Annamycin clinical trials, specifically highlighting a 38% complete response rate in the MB-106 acute myeloid leukemia trial. Additionally, the MB-107 trial indicated a median overall survival of 11 months for heavily pre-treated patients. Notably, all subjects across multiple trials experienced no cardiotoxicity, suggesting a significant advantage of Annamycin over existing therapies. However, some participants faced disease progression, and trial recruitment was impacted by a Serious Adverse Event unrelated to Annamycin itself.
Read more →MBRXMoleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
Moleculin Biotech, Inc. announced it will report its financial results for the third quarter on November 13, 2023. Following the report, the management will host a conference call and webcast to discuss the results. The company is focused on developing novel treatments for hard-to-treat tumors and viruses, with active Phase 2 clinical programs underway.
Read more →MBRX▲ +15%on this newsshared move
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Moleculin Biotech, Inc. presented positive preliminary efficacy findings from its ongoing Phase 1B/2 clinical trial of Annamycin for treating soft tissue sarcoma lung metastases at the 2023 CTOS Annual Meeting. The study revealed that 64% of participants experienced stable disease after two treatment cycles, with Annamycin showing no cardiotoxicity. The drug is currently recognized with Fast Track Status and Orphan Drug Designation by the FDA. Despite these promising results, the company acknowledges the necessity for further data to fully assess Annamycin's potential.
Read more →MBRX▲ +5.6%on this news
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Moleculin Biotech, Inc. announced its participation in the Virtual Investor Ask the CEO Conference on October 25, 2023. CEO Walter Klemp and CFO Jonathan Foster will engage with investors during this live event, allowing participants to submit questions. The conference aims to provide direct access to company management for discussions regarding Moleculin's clinical stage portfolio, which targets hard-to-treat tumors and viruses. A video webcast of the event will be available on the company's website for those who cannot attend live.
Read more →MBRXMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc. has initiated the Phase 2 portion of its clinical trial evaluating Annamycin in combination with Cytarabine for acute myeloid leukemia (AML). The earlier Phase 1B trial showed a 33% complete response rate, indicating potential efficacy. Annamycin, which seeks to minimize cardiotoxicity and overcome drug resistance, has already received FDA Fast Track Status and Orphan Drug Designation. This milestone represents a crucial step in the company's effort to develop new treatment options for AML.
Read more →MBRX▲ +9.9%on this news
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
Moleculin Biotech has completed enrollment in its Phase 2 clinical trial of Annamycin for treating soft tissue sarcoma lung metastases, marking a significant milestone. Preliminary results indicate over 60% of subjects exhibited stable disease following treatment. Annamycin is recognized by the FDA with Fast Track Status and Orphan Drug Designation. The company anticipates upcoming data readouts and further insights by the end of the year.
Read more →MBRXMoleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
Moleculin Biotech, Inc. announced positive findings regarding its drug Annamycin, which has shown no evidence of cardiotoxicity based on a review of data from 62 subjects in various clinical trials. The drug, a next-generation anthracycline, has shown both safety and early efficacy, particularly in treating acute myeloid leukemia and soft tissue sarcoma lung metastases. The independent assessment reaffirms the Company's belief that Annamycin can address significant unmet medical needs in oncology.
Read more →MBRXMoleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Moleculin Biotech, Inc. announced that its abstract has been accepted for poster presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting in Dublin, scheduled for November 1-4, 2023. The presentation will focus on a Phase 1b/2 study of Liposomal Annamycin for patients with previously treated soft-tissue sarcomas and pulmonary metastases, highlighting the company's ongoing development of therapies for difficult-to-treat cancers. The lead presenter will be Dr. Brian Andrew Van Tine from Washington University School of Medicine.
Read more →MBRXMoleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Moleculin Biotech, Inc. (Nasdaq: MBRX) will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Walter Klemp will lead the presentation, and the company aims to engage with investors through virtual one-on-one meetings. A video webcast of the presentation will be available for registered attendees and archived for 90 days on the company's website. Moleculin specializes in developing treatments for hard-to-treat tumors and has a growing pipeline that includes advanced-stage clinical programs.
Read more →MBRXMoleculin Reports Second Quarter 2023 Financial Results
Moleculin Biotech, Inc. reported its financial results for the second quarter of 2023, highlighting positive progress in their clinical development pipeline. The company disclosed preliminary efficacy data from its Phase 1B/2 clinical trial involving Annamycin for treating soft tissue sarcoma, while also announcing successful completion of the Phase 1B trial for AML. Despite a decrease in R&D and general expenses, Moleculin continues to face net losses, but has adequate cash reserves projected to last until late 2024. The company remains focused on advancing its priority programs and addressing the medical needs of patients with resistant cancers and viruses.
Read more →MBRXMoleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
Moleculin Biotech provided an encouraging update on its ongoing clinical trials, reporting the successful completion of the Phase 1B portion of the Annamycin trial for acute myeloid leukemia (AML) and an impressive efficacy rate in soft tissue sarcoma patients. Preliminary data shows a 33% CR/CRi rate in AML and 73% stable disease rates in soft tissue sarcoma after treatment cycles. The company signals continued progress with upcoming milestones expected in 2023, while managing safety and recruitment challenges in its trials.
Read more →MBRXMoleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling
Moleculin Biotech, Inc. has announced the retention of Shareholder Intelligence Services, LLC to investigate potential naked short selling of its stock. This investigation aims to enhance shareholder transparency by providing detailed data regarding stock ownership and trading patterns. CEO Walter Klemp expressed the company's commitment to acting in its fiduciary capacity while supporting ongoing clinical programs. Moleculin continues to develop a robust pipeline of drug candidates for challenging tumors and viruses, including its lead program Annamycin for treating specific cancers.
Read more →MBRXMoleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast
Moleculin Biotech, Inc. plans to report its second quarter financial results for 2023 on August 11, 2023. A conference call and live audio webcast will be held at 8:30 AM ET to discuss both operational and financial outcomes. Notably, Moleculin is developing innovative drug candidates aimed at treating highly resistant tumors and viruses, including their lead program, Annamycin, for acute myeloid leukemia and soft tissue sarcoma.
Read more →MBRXMoleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc. announced the publication of positive data from its MB-105 European Phase 1 trial, where Annamycin was evaluated as a single agent for relapsed or refractory acute myeloid leukemia (AML). The trial demonstrated promising efficacy, with an 80% overall response rate and no evidence of cardiotoxicity in treated subjects. Following these encouraging outcomes, Annamycin is now being advanced into a Phase 1b/2 trial in combination with Cytarabine for further evaluation. The publication in the British Journal of Cancer Research emphasizes the study's scientific credibility.
Read more →MBRXMoleculin to Participate in the Virtual Investor Summer Spotlight Series
Moleculin Biotech, Inc. announced its participation in the Virtual Investor Summer Spotlight Series, scheduled for July 12, 2023. The event will feature CEO Walter Klemp and CFO Jon Foster, highlighting the company's ongoing development efforts in cancer and virus resistance. Moleculin boasts a diverse pipeline, including drug candidates like Annamycin for leukemia and WP1066 targeting various cancers. The presentation will be accessible online, providing an opportunity for investors to engage with the company's strategies.
Read more →MBRXMoleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Moleculin Biotech, Inc. will participate in a Healthcare Virtual Conference on June 21, 2023, where CEO Walter Klemp and CFO Jonathan Foster will present. The conference, hosted by M-Vest, will feature a range of biotechnology and medical device companies discussing key data-driven events. Moleculin is recognized for its advanced pipeline, including Phase 2 clinical programs focusing on hard-to-treat tumors and viruses. Their lead program Annamycin aims to treat relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
Read more →MBRXMoleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023
Moleculin Biotech has announced the adjournment of its 2023 Annual Meeting to June 15, 2023, to allow additional voting on its reverse stock split proposal. Although a significant portion of votes already favors the proposal, the company is seeking further input from stockholders, as the proposal needs majority approval of all outstanding shares. While the reverse split has gained support from leading proxy advisory firms, the company faced setbacks with the rejection of other proposals at the meeting. The focus remains on maintaining a strong Nasdaq listing and advancing its clinical development plans.
Read more →MBRXMoleculin Reports First Quarter 2023 Financial Results
Moleculin Biotech, Inc. reported its financial results for the first quarter of 2023, highlighting the progress in its development programs including positive clinical data. The company has sufficient capital to support operations through the third quarter of 2024 and is preparing for important clinical data readouts throughout the year. Despite a reported net loss of $7.915 million and increased R&D expenses, the company remains optimistic about its pipeline addressing hard-to-treat tumors and viruses.
Read more →MBRXMoleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
Moleculin Biotech, Inc. announced it will report its first quarter financial results on May 11, 2023. Management will host a conference call and webcast at 8:30 AM ET to discuss these results. The company is recognized for its clinical-stage drug candidates targeting resistant tumors and viruses, including its lead program, Annamycin, aimed at treating relapsed acute myeloid leukemia and soft tissue sarcoma metastases. This event highlights the company's commitment to transparency and investor engagement.
Read more →MBRXMoleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc. has successfully completed the first cohort of its Phase 1b/2 clinical trial evaluating Annamycin in combination with Cytarabine for treating acute myeloid leukemia (AML). Preliminary results showed a durable complete response in one elderly subject, while two others continued to show disease progression. Based on these positive initial outcomes, the company is advancing to the second cohort with an increased dosing schedule. Annamycin is designed to be non-cardiotoxic and aims to enhance treatment efficacy for relapsed or refractory AML patients.
Read more →MBRXMoleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models
Moleculin Biotech, Inc. announced positive preclinical data for Annamycin, presented at the AACR Annual Meeting 2023. The data indicated high antitumor activity in models of hepatocellular carcinoma and colon cancer liver metastases, along with significant drug accumulation in the liver. Annamycin is being developed as a non-cardiotoxic alternative to existing anthracyclines and is currently in clinical trials for acute myeloid leukemia and STS lung metastases. The promising results support further studies to assess its effectiveness in various tumor models.
Read more →MBRXMoleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
Moleculin Biotech, Inc. announced its financial results for the fiscal year ended December 31, 2022, highlighting significant progress in clinical programs, particularly with Annamycin. The company has received positive data, including an 80% overall response rate in a Phase 1 trial for Refractory AML, and has been granted Fast Track Designation by the FDA for WP1122. Despite a net loss of $29.0 million, Moleculin reported sufficient capital to support operations into the third quarter of 2024. The company will provide further insights during a conference call scheduled for March 23, 2023.
Read more →MBRXMoleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
Moleculin Biotech announced positive interim Phase 2 data from its soft tissue sarcoma (STS) lung metastases clinical trial, demonstrating promising efficacy and an absence of cardiotoxicity for its lead program, Annamycin. The company has reached 50% enrollment in the Phase 2 trial and expects to report topline data by the second half of 2023. Additionally, the firm is actively recruiting across multiple clinical trials, with significant milestones anticipated within the year. Despite some reported myelosuppression, the overall progress in their pipeline bolsters optimism for advancing treatment options.
Read more →MBRXMoleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Moleculin Biotech, Inc. announced that its abstract on Annamycin has been accepted for a poster presentation at the AACR Annual Meeting 2023. The presentation will focus on Annamycin's potential in targeting primary and metastatic liver cancers. Annamycin is notable for its accumulation in the lungs and lack of cardiotoxicity compared to traditional anthracyclines like doxorubicin. The Company is developing Annamycin for use in acute myeloid leukemia and soft tissue sarcoma lung metastases, positioning it as a promising candidate in cancer therapy.
Read more →MBRXMoleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast
Moleculin Biotech, Inc. announced it will report its full year 2022 financial results on March 22, 2023, after market close. A conference call and live audio webcast will follow on March 23, 2023, at 8:30 AM ET with the company's leadership team. Moleculin is a clinical-stage pharmaceutical company focusing on innovative therapies for challenging tumors and viruses, with several programs currently in Phase 2. The company aims to engage with investors and provide insights into its operational and financial performance during the upcoming event.
Read more →MBRXMoleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference
Moleculin Biotech, Inc. announced that its Chief Financial Officer, Jonathan P. Foster, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. The presentation will include a live video webcast, and management will be available for one-on-one meetings with investors. Moleculin is a clinical stage pharmaceutical company focusing on innovative therapies for challenging tumors and viruses, with a pipeline that includes promising candidates like Annamycin and WP1066.
Read more →MBRXMoleculin Announces it Has No Exposure to Silicon Valley Bank Situation
Moleculin Biotech, Inc. announced that it has no deposits or investments with Silicon Valley Bank, which recently came under control of the Federal Deposit Insurance Corp. due to liquidity issues. The company emphasizes its growing pipeline focused on treatments for hard-to-treat tumors and viruses. Notable programs include Annamycin for acute myeloid leukemia and WP1066 for targeting various cancers.
Read more →MBRXMoleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Moleculin Biotech, Inc. announced the publication of promising data on Annamycin, a non-cardiotoxic anthracycline designed for cancer treatment, in the European Journal of Cancer. The review highlighted Annamycin's ability to avoid typical cardiotoxic effects associated with existing anthracyclines. Current clinical evaluations show its efficacy against soft tissue sarcoma and acute myelogenous leukemia, with a unique mechanism that enhances its potency against multidrug resistant tumors. The encouraging findings support further development of Annamycin as a safer option for cancer therapy.
Read more →MBRXMoleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech announced the commencement of dosing for the first subject in Italy as part of its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine for treating acute myeloid leukemia (AML). This follows encouraging data from previous trials, showing Annamycin's potential effectiveness without significant cardiotoxicity. The company aims to expand recruitment across additional sites to bolster trial enrollment. However, they acknowledge uncertainties related to the trial's outcomes and recruitment efforts.
Read more →MBRXMoleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Moleculin Biotech announced promising topline results from its European Phase 1 trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML). The trial revealed an 80% overall response rate in elderly participants and confirmed no cardiotoxicity among subjects. The company plans to further investigate Annamycin's efficacy in combination with Cytarabine in ongoing trials. These results underscore the potential of Annamycin as a treatment alternative for AML, particularly given the absence of typical anthracycline-related cardiac risks.
Read more →MBRXMoleculin to Present at the Virtual Investor 2023 Companies to Watch Event
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its CEO, Walter Klemp, will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023. The presentation will provide insights into Moleculin's portfolio of drug candidates that target highly resistant tumors and viruses. Notably, the company is advancing its lead program, Annamycin, for treating acute myeloid leukemia and other oncological indications. A live webcast will be available for investors and interested parties.
Read more →MBRXMoleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
– Ongoing efforts to open additional clinical sites in Poland and to gain approval to proceed in other European countries – First subject treated in Italy expected in the first quarter of 2023 HOUSTON, Dec. 21, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Molec
Read more →MBRXMoleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity across multiple clinical studies with potential to b
Read more →MBRXMoleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
HOUSTON, Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Dr
Read more →MBRXMoleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
– Continued execution across clinical and preclinical development programs – Three Phase 1b/2 clinical studies with enrollment or dosing now underway – Sufficient capital to fund operations beyond mid-2024 – Company to host conference call and webcast today at 5:00 PM ET HOUS
Read more →MBRXMoleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast
HOUSTON, Nov. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its f
Read more →MBRXMoleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Company enters what it expects to be the final MAD cohort in the first-in-human Phase 1a designed to establish a maximum tolerated dose (MTD) HOUSTON, Oct. 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceu
Read more →MBRXMoleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
– Preclinical work being conducted is intended to validate in vitro findings in established animal models to determine if further preclinical development and human clinical trials are warranted – Hemorrhagic fever arenaviruses (HFA) represent area of significant unmet need with
Read more →MBRXMoleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
– Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28th at 11:00 AM ET HOUSTON, Sept. 23, 2022 /PRNewswire/ -- Moleculi
Read more →MBRXMoleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
HOUSTON, Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of manageme
Read more →MBRXMoleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presi
Read more →MBRXMoleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
- Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of dr
Read more →MBRXMoleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
– Preliminary results of third cohort in the first-in-human Phase 1a allows Company to proceed to next single ascending dose (SAD) of 64 mg/kg dose and the first multiple ascending dose (MAD) cohort to commence with 32 mg/kg dose of WP1122 – HOUSTON, Aug. 19, 2022 /PRNewswire/ -
Read more →MBRXMoleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
- Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 - Company has sufficient capital to fund operations beyond mid-2024 HOUSTON, Aug. 15, 2022 /PRNewswire/ -- Moleculi
Read more →MBRXMoleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
– Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better – Company determines RP2D to be 360 mg/m2 and will begin Phase 2 recruitment – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue s
Read more →MBRXMoleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
– Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in third cohort toward establishing maximum tolerated dose (MTD) – – Multiple ascending dose (MAD) cohort to commence after completion of at least 3 successf
Read more →MBRXMoleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
– Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD) – – Multiple ascending dose (MAD) cohort to commence after completion of at least 3 success
Read more →MBRXMoleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD dosing cohorts in which WP1122 is
Read more →MBRXMoleculin to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presid
Read more →MBRXMoleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
– Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies – – Multiple key clinical and regulatory milestones expected throughout 2022 – – Company has sufficient capital to fund operations into 2024 – HOUSTON, M
Read more →MBRXMoleculin Receives Approval from the UK
– Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence imminently – HOUSTON, May 10, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or
Read more →MBRXMoleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
– Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine – Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine combined compared to Annamyci
Read more →MBRXMoleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer
Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomas Company continues to advance clinical development across priority developme
Read more →MBRXMoleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
Investigational New Drug (IND) application clearance from FDA opens up potential for additional investigator funded and led clinical studies HOUSTON, April 21, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceu
Read more →MBRXMoleculin Announces Corporate Rebranding and Launch of New Website
Company reiterates commitment to solving some of the toughest challenges in highly resistant cancers and viruses and developing better treatments that can make a real impact in people's lives HOUSTON, April 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Molec
Read more →MBRXMoleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting
Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients HOUSTON, April 8, 2022 /PRNewswire
Read more →MBRXMoleculin Reports Full Year Financial Results and Provides Programs Update
– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine – – Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute Myeloid Leukemia (AML) and metast
Read more →MBRXMoleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
HOUSTON, March 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chai
Read more →MBRXMoleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference
HOUSTON, March 11, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chai
Read more →MBRXMoleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors
HOUSTON, March 1, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the appointment of Joy Y
Read more →MBRXMoleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
HOUSTON, Feb. 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced preliminary results supp
Read more →MBRXMoleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founde
Read more →MBRXMoleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma
HOUSTON, Jan. 18, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported that it has received an u
Read more →MBRXMoleculin to Present at the H.C. Wainwright BioConnect Conference
HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presid
Read more →MBRXMoleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
HOUSTON, Dec. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary interim resul
Read more →MBRXMoleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
HOUSTON, Dec. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Adm
Read more →MBRXMoleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
HOUSTON, Nov. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder
Read more →MBRXMoleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
HOUSTON, Nov. 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for
Read more →MBRXMoleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
HOUSTON, Oct. 19, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received authorizatio
Read more →MBRXMoleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
HOUSTON, Oct. 18, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported interim results from its
Read more →MBRXMoleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
HOUSTON, Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presiden
Read more →MBRXMoleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presiden
Read more →MBRXMoleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President
Read more →MBRXMoleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
HOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for th
Read more →MBRXMoleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
HOUSTON, July 13, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received app
Read more →MBRXMoleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
HOUSTON, June 21, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has commenced enrollm
Read more →MBRXMoleculin Announces Inclusion in the Russell 2000® Index
HOUSTON, June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annu
Read more →MBRXMoleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
HOUSTON, May 25, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received clearance
Read more →MBRXMoleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
HOUSTON, May 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the
Read more →MBRXMoleculin Biotech to Present at the Q2 Virtual Investor Summit
HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Presid
Read more →MBRXMoleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
HOUSTON, April 14, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and
Read more →MBRXMoleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
HOUSTON, April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA Biot
Read more →MBRXMoleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
HOUSTON, March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020
HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for t
Read more →MBRXMoleculin to Participate in Four Upcoming Healthcare Conferences
HOUSTON, March 9, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management w
Read more →MBRXMoleculin Announces Full Exercise of Over-Allotment Option
HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of
Read more →MBRXMoleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases
HOUSTON, Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycz
Read more →MBRXMoleculin Announces Pricing Of $67.8 Million Underwritten Public Offering
HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwr
Read more →MBRXMoleculin Announces Proposed Underwritten Public Offering
HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it intends to offer
Read more →MBRXMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in a
Read more →MBRXMoleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreeme
Read more →MBRXMoleculin to Present at the H.C. Wainwright BioConnect 2021 Conference
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management wi
Read more →MBRXMoleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
HOUSTON, Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Ad
Read more →MBRXMoleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
HOUSTON, Dec. 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Ad
Read more →MBRXMoleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal d
Read more →MBRXMoleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Adm
Read more →MBRXMoleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML
HOUSTON, Nov. 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that new animal data has sho
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
HOUSTON, Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for th
Read more →MBRXMoleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
HOUSTON, Oct. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has entered into an a
Read more →MBRXMoleculin to Participate in Panel at ROTH Capital
HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that me
Read more →MBRXMoleculin Announces Independent Study Validates Annamycin
HOUSTON, Oct. 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced results
Read more →MBRXMoleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
HOUSTON, Oct. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced additio
Read more →MBRXMoleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV
HOUSTON, Oct. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced prelimin
Read more →MBRXMoleculin Appoints Elizabeth Cermak to Board of Directors
HOUSTON, Oct. 5. 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, today announced th
Read more →MBRXMoleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University
HOUSTON, Oct. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced prelimin
Read more →MBRXMoleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites
HOUSTON, Sept. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that i
Read more →MBRXMoleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
HOUSTON, Sept. 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has contracted
Read more →MBRXMoleculin to Present at Upcoming Healthcare Investor Conferences
HOUSTON, Sept. 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of managem
Read more →MBRXMoleculin Announces Successful Completion of Pre-IND Meeting with the FDA
HOUSTON, Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it successfully com
Read more →MBRXMoleculin to Present at LD Micro 500 Virtual Investor Conference
HOUSTON, Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chie
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Quarter Ended
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020 HOUSTON, August 12, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ta
Read more →MBRXAdditional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target
HOUSTON, July 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a recent publicatio
Read more →MBRXMoleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus HOUSTON
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus HOUSTON, July 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio
Read more →MBRXMoleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate HOUSTON
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate HOUSTON, July 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with
Read more →MBRXMoleculin Provides Update on Annamycin Clinical Development HOUSTON
Moleculin Provides Update on Annamycin Clinical Development HOUSTON, July 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant
Read more →MBRXNew Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model Findings published in Clinical Cancer Research HOUSTON
New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model Findings published in Clinical Cancer Research HOUSTON, July 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"),
Read more →MBRXMoleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases Data Presented at the AACR Annual Meeting HOUSTON
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases Data Presented at the AACR Annual Meeting HOUSTON, June 25, 2020 /PRNewswire/ - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company
Read more →MBRXMoleculin to Present at the Life Sciences Investor Forum
HOUSTON, June 23, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chie
Read more →MBRXMoleculin Announces Confirmatory In Vitro Analysis of WP1122 Receives feedback from FDA on Pre-IND meeting HOUSTON
Moleculin Announces Confirmatory In Vitro Analysis of WP1122 Receives feedback from FDA on Pre-IND meeting HOUSTON, June 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfol
Read more →MBRXMoleculin Announces Submission to Expand Clinical Sites in European AML Trial
HOUSTON, June 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for app
Read more →MBRXMoleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
HOUSTON, June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in th
Read more →MBRXMoleculin Announces Common Stock Will Resume Trading on the NASDAQ on
Moleculin Announces Common Stock Will Resume Trading on the NASDAQ HOUSTON, May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly re
Read more →MBRXMoleculin Provides Update on Coronavirus Drug Development FDA grants Pre-IND Meeting request HOUSTON
Moleculin Provides Update on Coronavirus Drug Development FDA grants Pre-IND Meeting request HOUSTON, May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug cand
Read more →MBRXMoleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information HOUSTON
Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information HOUSTON, May 18, 2020 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
Read more →MBRXMoleculin Provides Additional Comments Regarding Trading Halt HOUSTON
Moleculin Provides Additional Comments Regarding Trading Halt HOUSTON, May 11, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistan
Read more →MBRXMoleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
HOUSTON, May 8, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020 Annu
Read more →MBRXMoleculin Announces Trading Halt
HOUSTON, May 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced securities of the Company have been pl
Read more →MBRXMoleculin to Speak on COVID-19 Panel at Maxim Group
HOUSTON, April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chi
Read more →MBRXMoleculin Approved to Accelerate European Clinical Trial
HOUSTON, April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of
Read more →MBRXMoleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery Joins Moleculin's Science Advisory Board HOU
Read more →MBRXMoleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
HOUSTON, April 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has entered into an agreement with ImQuest Biosciences to exp
Read more →MBRXMoleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Today
HOUSTON, April 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, announced that Walter Klemp, Chairman and Chief Executive Officer, will host a web-ba
Read more →MBRXMoleculin Announces Leading Virologist Joins Development Team Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 HOUSTON
Moleculin Announces Leading Virologist Joins Development Team Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 HOUSTON, April 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical s
Read more →MBRXMoleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100% HOUSTON
Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100% HOUSTON, April 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Mo
Read more →MBRXMoleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100% Independent research shows 2-DG activity against virus that causes COVID-19 HOUSTON
Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100% Independent research shows 2-DG activity against virus that causes COVID-19 HOUSTON, April 8, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company
Read more →MBRXMoleculin Announces Additional Positive Safety Data in EU AML Trial A Total of 19 Patients Now Have Shown No Signs of Cardiotoxicity HOUSTON
Moleculin Announces Additional Positive Safety Data in EU AML Trial A Total of 19 Patients Now Have Shown No Signs of Cardiotoxicity HOUSTON, April 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical co
Read more →MBRXMoleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate
HOUSTON, March 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has b
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Year Ended
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019 HOUSTON, March 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ta
Read more →MBRXMoleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, including Coronavirus Independent research suggests new approach to inhibiting the viral replication capability of a range of viruses, including C
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, including Coronavirus Independent research suggests new approach to inhibiting the viral replication capability of a range of viruses, including Coronavirus HOUSTON, March 17, 2020 /PRNewswire/ -- Molecul
Read more →MBRXMoleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in China HOUSTON
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in China HOUSTON, March 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
Read more →MBRXMoleculin Issues Video Shareholder Letter HOUSTON
Moleculin Issues Video Shareholder Letter HOUSTON, March 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today iss
Read more →MBRXMoleculin Issues Video Shareholder Letter
HOUSTON, March 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today issued a video letter to its shareholders from
Read more →MBRXMoleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date Supports Moleculin's Claim that Annamycin is a "Next Generation" Anthracycline HOUSTON
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date Supports Moleculin's Claim that Annamycin is a "Next Generation" Anthracycline HOUSTON, February 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or th
Read more →MBRXMoleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions Data Presented at the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona HOUSTON
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions Data Presented at the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona HOUSTON, February 18, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Molecul
Read more →MBRXMoleculin Announces $6.0 Million Registered Direct Offering
HOUSTON, Feb. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive a
Read more →MBRXMoleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial Following Successful Completion of US Phase 1 Trial HOUSTON
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial Following Successful Completion of US Phase 1 Trial HOUSTON, February 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutic
Read more →MBRXMoleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1 trial results in
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1 trial results in Europe HOUSTON, February 3, 2020 /PRNewswire/ -- Moleculi
Read more →MBRXmbrxexh991q12020investor Developing ground-breaking therapies for highly resistant cancers
Developing ground-breaking therapies for highly resistant cancers January 12, 2020 Public Corporate Presentation (Nasdaq: MBRX) Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations an
Read more →MBRXMoleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models Annamycin shows unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumors HOUSTON, TX
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models Annamycin shows unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumors HOUSTON, TX - December 19, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Molecul
Read more →MBRXMoleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia No evidence of cardiotoxicity to date; 40% of 10 patients dosed at 120 mg/m 2 demonstrate eff
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia No evidence of cardiotoxicity to date; 40% of 10 patients dosed at 120 mg/m2 demonstrate efficacy; trial progresses in Europe to 210 mg/m2 HOUSTON, TX
Read more →MBRXMoleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lympho
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 study HOUSTON, TX - November 19, 2019
Read more →MBRXMoleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its dr
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019 HOUSTON, TX - November 12, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candi
Read more →MBRXMoleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial Approval gives green light to study of WP1066 for treatment of pediatric brain cancer HOUSTON, TX
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial Approval gives green light to study of WP1066 for treatment of pediatric brain cancer HOUSTON, TX - November 12, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
Read more →MBRXMoleculin Announces New Data Confirms Anti- tumor Efficacy of Annamycin in Both Human and Murine AML Models Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference HOUSTON, TX
Moleculin Announces New Data Confirms Anti- tumor Efficacy of Annamycin in Both Human and Murine AML Models Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference HOUSTON, TX - October 29, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Mole
Read more →MBRXMoleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications Expansion of potential indications includes lung-localized tumors HOUSTON, TX
Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications Expansion of potential indications includes lung-localized tumors HOUSTON, TX - October 22, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Co
Read more →MBRXMoleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
HOUSTON, Sept. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its sponsored research at MD Anders
Read more →MBRXMoleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial
HOUSTON, Aug. 20, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced approval by the Emory University Cli
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019 HOUSTON, TX - August 16, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates
Read more →MBRXMoleculin Announces Completion of Lymphoma Trial Enrollment HOUSTON
HOUSTON - August 13, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin"or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to evaluate
Read more →MBRXMoleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models Data to be presented at the Inaugural Conference on Brain Metastases, August 16-17, 2019 HOUSTO
HOUSTON - August 6, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a paper entitled "Immunological Reprogrammi
Read more →MBRXMoleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3 rd Cohort HOUSTON
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort HOUSTON - July 18, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Read more →MBRXMoleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
HOUSTON, July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the
Read more →MBRXmbrxexhibit991q22019inve Developing breakthrough therapies for highly resistant cancers May 2019 Corporate Presentation (Nasdaq: MBRX) 1 Disclaimer All statements contained herein other than statements of historical fact
Developing breakthrough therapies for highly resistant cancers May 2019 Corporate Presentation (Nasdaq: MBRX) 1 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial posi
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019 HOUSTON - May 14, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
Read more →MBRXMoleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe 2 of 3 patients qualify to proceed to a potentially curative bone mar
Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe 2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level H
Read more →MBRXUS Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment
HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (NASDAQ: MBRX),
Read more →MBRXMoleculin Biotech, Inc., General Corporate Update Call Wednesday
Moleculin Biotech, Inc., General Corporate Update Call Wednesday, April 24, 2019, 4:30 PM Eastern CORPORATE PARTICIPANTS Wally Klemp - Chairman, Chief Executive Officer Jonathan P. Foster - Executive Vice President, Chief Financial Officer Moleculin Biotech, Inc., Wednesday, Ap
Read more →MBRXMoleculin Announces $15.0 Million Registered Direct Offering HOUSTON
$15.0 Million Registered Direct Offering HOUSTON - April 23, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that
Read more →MBRXMoleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019
HOUSTON, April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it will host a conference call to d
Read more →MBRXMoleculin Receives FDA Approval of Fast Track Designation for Annamycin
HOUSTON, April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Adminis
Read more →MBRXMoleculin Announces Significant Discovery in Lung Cancer Models
HOUSTON, April 17, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its ongoing sponsored research
Read more →MBRXMoleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial HOUSTON
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial HOUSTON - April 11, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Read more →MBRXMoleculin Announces Successful Expansion of its Leukemia Drug Program
HOUSTON, April 9, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the cli
Read more →MBRXMoleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting
HOUSTON, April 3, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that preclinical data supporting act
Read more →MBRXMoleculin Announces Pricing Of Underwritten Public Offering
HOUSTON, March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten publ
Read more →MBRXMoleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland One patient to proceed to potentially curative bone marrow transpl
Moleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland One patient to proceed to potentially curative bone marrow transplant; no cardiotoxicity observed HOUSTON - March 26, 2019
Read more →MBRXMoleculin Announces Proposed Underwritten Public Offering HOUSTON
Moleculin Announces Proposed Underwritten Public Offering HOUSTON - March 26, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, to
Read more →MBRXMoleculin Announces First Patients Enrolled in Lymphoma Clinical Trial
HOUSTON, March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have be
Read more →MBRXNASDAQ: MBRX Non-Confidential Information
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements.
Read more →MBRXMoleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference
HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texa
Read more →MBRXMoleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board
HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Dr. Martin Tallman, Chief of L
Read more →MBRXMoleculin Announces First Patients Treated in European Annamycin Clinical Trial HOUSTON
Moleculin Announces First Patients Treated in European Annamycin Clinical Trial HOUSTON - March 14, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly r
Read more →MBRXMoleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXMoleculin Announces Approval for Third Drug to Commence Clinical Trials MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in
Moleculin Announces Approval for Third Drug to Commence Clinical Trials MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona ("C
Read more →MBRXMoleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug HOUSTON
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug HOUSTON - February 5, 2019 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candi
Read more →MBRXMoleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXNASDAQ: MBRX Non - Confidential Information January 14, 201 9 1 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and fin
NASDAQ: MBRX Non - Confidential Information January 14, 201 9 1 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our o
Read more →MBRXMoleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland
Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology d
Read more →MBRXNASDAQ: MBRX Non - Confidential Information January 7, 201 9 1 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and fina
NASDAQ: MBRX Non - Confidential Information January 7, 201 9 1 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our ob
Read more →MBRXMoleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
HOUSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXCall to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday
Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018 Welcome to Moleculin Biotech, Inc.'s Conference Call to provide a general corporate update and to discuss positive developments regarding the Company's drug development pipeline. First -
Read more →MBRXMoleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXMoleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXMoleculin Announces Breakthrough Discovery for its WP1066
WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of
Read more →MBRXMoleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are
Read more →MBRXMoleculin Requests FDA Meeting Regarding IND for New Cancer Drug
Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all o
Read more →MBRXMoleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122
Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the develo
Read more →MBRXMoleculin Announces Significant Milestone Achieved in Glioblastoma Trial
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug can
Read more →MBRXMoleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXPROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. Yo
This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the "Risk Factors"
Read more →MBRXMoleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors
Data to be Presented at Neuro-Oncology Annual Scientific Meeting HOUSTON, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all
Read more →MBRXMoleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- In the ongoing challenge to combat the
Read more →MBRXMoleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial
HOUSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXMoleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of T
Read more →MBRXMoleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Tex
Read more →MBRXMoleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover
HOUSTON, July 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Te
Read more →MBRXMoleculin Selected for the Russell Microcap Index
HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Te
Read more →MBRXMoleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market
HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of which are based on license agreements with The University of
Read more →MBRXMoleculin Receives Approval for Leukemia Clinical Trial HOUSTON
Moleculin Receives Approval for Leukemia Clinical Trial HOUSTON - June 20, 2018 - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on lic
Read more →MBRXMoleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
HOUSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Tex
Read more →MBRXMoleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
HOUSTON, June 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Te
Read more →MBRXMoleculin Invited to Present to International BioForum 2018 Conference
HOUSTON, May 24, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Tex
Read more →MBRXMoleculin to Begin Clinical Trials at UMC Southwest Cancer Center
HOUSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Tex
Read more →MBRXMoleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial
HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Tex
Read more →MBRXMoleculin Biotech, Inc. Unaudited Condensed Balance Sheets (in thousands)
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017 HOUSTON - March 28, 2018 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidate
Read more →MBRXMoleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment Cutting Edge Science Suggests New Molecule is Capable of Shutting Down Tumor Activity HOUSTON
Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment Cutting Edge Science Suggests New Molecule is Capable of Shutting Down Tumor Activity HOUSTON - February 15, 2018 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinic
Read more →MBRXMoleculin Announces Activity with Pancreatic Cancer Drug HOUSTON
Moleculin Announces Activity with Pancreatic Cancer Drug HOUSTON - February 7, 2018 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are base
Read more →MBRXMoleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors HOUSTON
MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors November 1, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candi
Read more →MBRXMoleculin Requests Authorization from the Polish Government to Advance Annamycin HOUSTON
Moleculin Requests Authorization from the Polish Government to Advance Annamycin HOUSTON - October 24, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candida
Read more →MBRXMoleculin Announces FDA Approval of Annamycin
Moleculin Announces FDA Approval of Annamycin HOUSTON - September 26, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on li
Read more →MBRXMoleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center HOUSTON
Moleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center HOUSTON - July 25, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-
Read more →MBRXJon - Disclaimer Hello, this is Jon Foster, CFO of Moleculin Biotech, Inc. and I would like to welcome you to our conference call. Before we begin, I'd like to provide some important disclosures: Some of the statements i
Hello, this is Jon Foster, CFO of Moleculin Biotech, Inc. and I would like to welcome you to our conference call. Before we begin, I'd like to provide some important disclosures: Some of the statements in this conference call will be forward-looking statements within the meani
Read more →MBRXMoleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines HOUSTON
Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines HOUSTON - June 21, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical
Read more →MBRXMoleculin Announces Preparation to File an IND with the FDA for WP1220 for Treatment of Cutaneous T-Cell Lymphoma HOUSTON
Announces Preparation to File an IND with the FDA for WP1220 for Treatment of Cutaneous T-Cell Lymphoma HOUSTON - June 13, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-can
Read more →MBRXMoleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin HOUSTON
Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin HOUSTON - May 23, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-
Read more →MBRXMoleculin Biotech Appoints Theradex Systems as CRO to Manage Phase I/II Annamycin Trial HOUSTON
Moleculin Biotech Appoints Theradex Systems as CRO to Manage Phase I/II Annamycin Trial HOUSTON - April 11, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candi
Read more →MBRXMoleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended
Moleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 Recently Received Orphan Drug Designation HOUSTON - April 3, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical c
Read more →MBRXMoleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia HOUSTON
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia HOUSTON - March 22, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-canc
Read more →MBRXNASDAQ : MBRX
NASDAQ : MBRX March 15, 2017 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, ar
Read more →MBRXAnnounces Pricing of $5 Million Underwritten
Announces Pricing of $5 Million Underwritten HOUSTON - February 9, 2017 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license
Read more →MBRXOPERATOR: Welcome to the Moleculin Biotech, Inc.'s Conference Call to provide a general corporate update and to discuss positive developments regarding Annamycin. First - let me introduce Jonathan P. Foster, Executive Vi
OPERATOR: Welcome to the Moleculin Biotech, Inc.'s Conference Call to provide a general corporate update and to discuss positive developments regarding Annamycin. First - let me introduce Jonathan P. Foster, Executive Vice President and Chief Financial Officer. JON: Thank you,
Read more →MBRXMoleculin Announces Accelerated Plan for Clinical Trial Drug Production Secures Assistance from European Partner, Reducing Expenditure and Time to Begin Clinical Trials for Annamycin HOUSTON
Moleculin Announces Accelerated Plan for Clinical Trial Drug Production Secures Assistance from European Partner, Reducing Expenditure and Time to Begin Clinical Trials for Annamycin HOUSTON-October 7, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Compa
Read more →MBRXMoleculin Biotech to Present at OktoberINVESTfest NEW YORK and HOUSTON
Moleculin Biotech to Present at OktoberINVESTfest NEW YORK and HOUSTON - September 23, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), today announces its upcoming presentation at the fifth annual OktoberINVESTfest presented by Joseph Gunnar & Co
Read more →MBRXAugust 2016 Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, an
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements
Read more →MBRXMoleculin Appoints New Chief Financial Officer Seasoned Financial Executive Jonathan P. Foster Joins Moleculin Biotech HOUSTON
New Chief Financial Officer Seasoned Financial Executive Jonathan P. Foster Joins Moleculin Biotech HOUSTON-August 22, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical and clinical-stage pharmaceutical company focused on the develo
Read more →MBRXMoleculin Expands Research Sponsorship at MD Anderson Cancer Center Facilitates Access to Grant Funding and Cutting Edge Research Capability HOUSTON
Moleculin Expands Research Sponsorship at MD Anderson Cancer Center Facilitates Access to Grant Funding and Cutting Edge Research Capability HOUSTON-August 9, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical and clinical-stage phar
Read more →MBRXMoleculin Announces Data on WP1122 Presented at the 28 th Annual International Carbohydrate Symposium -Establishes chemistry critical to clinical and subsequent commercial development of WP1122- HOUSTON and
Moleculin Announces Data on WP1122 Presented at the 28th Annual International Carbohydrate Symposium -Establishes chemistry critical to clinical and subsequent commercial development of WP1122- HOUSTON and NEW ORLEANS- July 28, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX)
Read more →MBRXMoleculin Announces Successful Engineering Run for Production of Annamycin HOUSTON
Moleculin Announces Successful Engineering Run for Production of Annamycin HOUSTON - July 19, 2016 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug
Read more →MBRXMoleculin Biotech, Inc. (Nasdaq: MBRX) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
ADVISORY, June 02, 2016 (GLOBE NEWSWIRE) -- Moleculin Biotech (Nasdaq:MBRX), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offeri
Read more →Competitive Position
How MBRX ranks across every disease it competes inCompetitive Position is a premium feature
See how MBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial